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COMBINATORIAL ACTIVATION OF STAT3
BY EGF AND THROMBIN IN ENDOTHELIAL CELLS

MATTHEW S. WAITKUS

ABSTRACT

Endothelial cells line the luminal surface of blood vessels and form a regulatory
interface between the bloodstream and underlying tissues. The endothelium responds to
diverse, and potentially conflicting, environmental signals to regulate vessel growth,
leukocyte adhesion, thrombogenicity, and vascular tone. Signaling pathways may
interact, or “crosstalk,” in combinatorial signaling environments to enable cells to process
disparate extracellular information at downstream signaling nodes and formulate
appropriate biological responses based on combinations of extracellular stimuli.
We have reported that simultaneous stimulation of endothelial cells with EGF and
thrombin synergistically induces expression of immediate early genes (IEGs) associated
with growth and angiogenesis. We sought to characterize the molecular mechanism of
EGF receptor (EGFR) and thrombin receptor (protease-activated receptor-1, PAR-1)
crosstalk that regulates synergistic IEG induction. Using a bioinformatic comparison of
IEG promoter regions, we identified the transcription factor STAT3 as a critical
integrator of EGF and thrombin-activated signaling pathways. Depletion of STAT3 by
RNAi completely abrogates synergistic IEG induction following EGFR/PAR-1
activation. Analysis of upstream signaling pathways by phosphoproteomic, RNAi, and
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pharmacological approaches demonstrated that GSK-3α/β-dependent phosphorylation of
STAT3 Ser727 is required for synergistic activation of the EGR1 promoter. Functionally,
combinatorial EGFR/PAR-1 signaling suppresses EGF-induced proliferation and
thrombin-induced leukocyte adhesion, and triggers a STAT3-dependent increase in
endothelial cell migration.
Next, we used quantitative liquid chromatography-tandem mass spectrometry
(LC-MS/MS) to examine the inducible flux and abundance of endogenous STAT3
phosphoforms. We identified and characterized a STAT3 phosphoform that is
simultaneously modified at Thr714 and Ser727 by GSK-3α/β. Both Thr714 and Ser727 are
required for STAT3-dependent gene induction in response to coincident EGFR/PAR-1
activation. In this combinatorial signaling context, preventing formation of doubly
phosphorylated STAT3, by depleting GSK-3α/β, is sufficient to disrupt signal integration
and inhibit STAT3-dependent gene expression. LC-MS/MS analysis of human renal
tumor extracts revealed that levels of doubly phosphorylated STAT3 are remarkably
elevated in patients with clear cell renal cell carcinoma, suggesting that the GSK-3α/βSTAT3 signaling axis may be active in this disease. Collectively, our results describe a
functionally distinct, noncanonical STAT3 phosphoform that is a critical integrator of
disparate signaling pathways in endothelial cells and positively regulates STAT3 target
gene expression in this context.
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CHAPTER I
INTRODUCTION

1.1

Mechanisms of Endothelial Activation
The vascular endothelium is a monolayer of cells that lines the entire luminal

surface of the vasculature and forms a regulatory interface between circulating blood
components and underlying tissue compartments. The endothelium covers a network of
blood vessels that exceeds 100,000 km in aggregate length, with a surface area of
approximately 5000 m2 (1). Its massive size and distribution into all organs and tissues
gives the endothelium the capacity to monitor physiological perturbations throughout the
entire body (1, 2). By virtue of its juxtaposition with circulating blood components, the
endothelium is critically situated to sense and respond to blood-borne stimuli on a
systemic scale, making it the body’s largest homeostatic organ (2).

1

Although it was originally considered a passive barrier, modern research has
uncovered numerous mechanisms by which the endothelium actively maintains vascular
homeostasis. Under physiological conditions, the endothelium prevents vasospasm,
resists leukocyte adhesion, inhibits smooth muscle cell proliferation, and acts as a nonthrombogenic surface for the entire circulatory system (2–4). The endothelium also acts
as a selective physical barrier by actively regulating the passage of macromolecules and
leukocytes into and out of the bloodstream (3). These physiological roles are influenced
by environmental stimuli that cause the endothelial phenotype to fluctuate between
antagonistic functions of vascular homeostasis. At different times or locations, the
endothelium can be non-adhesive or hyperadhesive to leukocytes, procoagulatory or
anticoagulatory, and act as a vasoconstrictor or vasodilator (2). In this way, the
endothelium displays a remarkable phenotypic plasticity to adapt to environmental
changes. These phenotypic changes are usually normal, adaptive responses to the
changing vascular environment and are an essential contribution to vascular homeostasis.
Localized, non-adaptive changes to endothelial physiology can also alter its
phenotype to induce changes in vessel tone, leukocyte adhesiveness, coagulation, and the
production of autocrine and paracrine factors, including vasorelaxants and vasospastic
substances (2, 3). These aberrant alterations are collectively referred to as endothelial
dysfunction, and they are involved in the initiation and progression of numerous
cardiovascular diseases. Endothelial activation is a distinct term that describes the
process by which bloodborne and environmental stimuli cause endothelial cells to
undergo dramatic functional changes and acquire new physiological properties (1).

2

Proper endothelial function is critical for maintaining vascular health, and
endothelial dysfunction may cause or contribute to numerous vascular diseases (2, 5).
This chapter will provide a brief overview of normal endothelial physiology that will
serve as a foundation for an in-depth explanation of the molecular mechanisms
underlying endothelial cell activation, as well as the contribution of endothelial cell
activation to the genesis and progression of vascular diseases.

1.1.1 Morphology, Barrier Function, and Biomechanical Signal Transduction
As a continuous monolayer of cells, the vascular endothelium forms an extensive
regulatory interface between the bloodstream and underlying tissues (6). Abundant
intercellular junctions including tight junctions, gap junctions, and adherens junctions
allow the endothelium to function as an active physical barrier (7–10). The relative
abundance of these junctions varies between anatomic locations and confers site-specific
specialization of endothelial permeability (3). Arteries and blood vessels of the brain
contain more tight junctions, which restrict macromolecular flux between intravascular
and extravascular compartments. Gap junctions, which consist of connexin proteins (11),
link the cytoplasm of neighboring endothelial cells, and likely play roles in intercellular
communication (10). Adherens junctions, which consist of cadherin proteins, are
important for endothelial cell organization, growth, and migration (1, 10).
The modulation of intercellular junctions via post-translational modifications of
junction proteins plays a role in the regulation of vascular permeability. The mechanisms
vary according to stimuli, but permeability is usually increased by phosphorylation of
junction proteins, actin-myosin-dependent morphological changes, and an increased
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number of intercellular gaps in the endothelial monolayer (3, 12–16). For example,
phosphorylation of the protein occludin, a component of tight junctions, can positively or
negatively regulate its expression depending on the type of mechanical force acting upon
the endothelium (13, 16). Furthermore, various inflammatory stimuli, including TNFα
and thrombin, activate the Rho-associated coiled-coil containing protein kinases 1 and 2
(ROCK1, ROCK2) (17–19). Activated ROCKs positively regulate myosin light chain
phosphorylation to increase actin-myosin contractility and endothelial permeability (20).
Under physiological conditions, these changes are controlled and reversible, and
represent adaptive control of macromolecular flux between the bloodstream and tissues.
Situated in direct contact with circulating blood, endothelial cells are constantly
exposed to a variety of hemodynamic forces including shear stress, hydrostatic pressure,
and cyclic strain. Shear stress is particularly significant because it is transduced by
endothelial cell-surface proteins to activate signaling pathways that regulate changes in
cell morphology, growth, and gene expression (21). The endothelial response to shear
stress depends on the type and rate of flow. For example, exposure of endothelial cells to
steady laminar flow may induce cell-cycle arrest in G0 or G1 by various mechanisms
including p53 activation and induction of p21 (22, 23). In contrast, exposure to disturbed
blood flow increases endothelial cell proliferation (6, 24, 25). Additionally, laminar flow
causes endothelial cells to become aligned and elongated in the direction of flow (26),
while disturbed flow causes endothelial cells to adopt a more polygonal shape without a
clear orientation (6, 27).
Fluid shear stress also modulates endothelial gene expression. Shear stress
response elements (SSRE) have been discovered in the promoters of many genes, and act
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as critical cis-acting elements for shear stress-regulated gene expression (28, 29).
Mechanotransducers, particularly integrins, at the endothelial cell-surface respond to
shear forces to activate signaling pathways and transcription factors that regulate gene
induction (30, 31). The exact mechanisms by which endothelial cell-surface proteins
transduce mechanical forces is not known, but cytoskeletal proteins, receptor tyrosine
kinases (RTKs), G-protein coupled receptors (GPCRs), and ion channels are all known to
play a role (13, 14, 16, 21). The ability of endothelial cells to react to specific types of
biomechanical forces emphasizes its role as a type of organism-wide sensory organ,
capable of detecting and responding to a variety of hemodynamic forces depending on
both the type and magnitude of the force.
Atherosclerotic lesions form at sites of disturbed blood flow in arterial vessels,
suggesting that changes in shear stress may alter patterns of atheroprotective or
atherogenic

gene

expression

(6).

Indeed,

numerous

reports

suggest

that

mechanotransduction of laminar flow and high shear stress is adaptive and
atheroprotective, while low-level shear stress or disturbed flow is atherogenic (6). The
mechanisms by which disturbed blood flow contributes to lesion formation are not
completely understood, but differences in the activation of signaling pathways between
laminar and disturbed flow have been observed. Both types of flow activate intracellular
signaling kinases and transcription factors including NF-κB, early growth response 1
(EGR1), activator protein 1 (AP1), and JUN N-terminal kinase (JNK) (21). Under
laminar flow, the activation of these molecules is transient, increasing over several hours
and then returning to basal levels. In contrast, EC exposed to disturbed flow show
sustained activation of kinases and transcription factors, including NF-κB and JNK,
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which coincides with increased expression of inflammatory genes, such as ICAM-1,
VCAM-1, E-selectin, MCP-1, ET-1, and PDGF (6, 21, 32, 33). The differences in the
kinetics of pathway activation and gene expression between laminar and disturbed flow
may represent a potential basis for the non-random formation of atherosclerotic lesions at
vessel bifurcations where blood flow is disturbed or slowed.

1.1.2 Regulation of Hemostasis and Vascular Tone
The endothelium acts as a regulator of vascular tone by synthesizing and secreting
vasodilatory or vasoconstrictive substances that act on underlying smooth muscle cells.
The most extensively studied endothelial-derived vasorelaxing factor is nitric oxide (NO)
(4), which is synthesized by the endothelial enzymes endothelial nitric oxide synthase
(eNOS) and inducible nitric oxide synthase (iNOS). NO exerts a local vasorelaxing effect
by diffusing into the smooth muscle cell and activating guanylate cyclase, thereby
increasing levels of cyclic guanosine monophosphate (cGMP) (34). Higher levels of
cGMP inhibit calcium entry into the smooth muscle cell, resulting in decreased
vasoconstriction (35, 36). Endothelial cells are also capable of synthesizing vasoactive
metabolites of arachadonic acid called eicosanoids. The most important eicosanoid for
maintaining physiological vessel tone is the vasorelaxant prostacyclin. Endothelial cells
express the enzymes cyclooxygenase-1,2 (COX-1, COX-2) which synthesize
prostaglandin H2 (PGH2) from arachidonic acid (35). PGH2 can then be converted to a
number of vasoactive metabolites, but endothelial cells express significant levels of the
enzyme prostacyclin synthase (37), thus favoring the formation of prostacyclin.
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Prostacyclin is secreted by endothelial cells and is a potent vasodilatory substance that
acts on smooth muscle cells to decrease vascular tone (2).
Availability of NO is dysregulated in a number of vascular pathologies, including
atherosclerosis and coronary artery disease (1). Reductions in NO availability occur
though multiple mechanisms, including decreased NO production or stabilization, and
inactivation by ROS (38, 39). Additionally, a number of endothelial-derived
vasoconstrictive substances, including ET-1, angiotensin II, and PDGF antagonize the
actions of NO and prostacyclin to induce smooth muscle cell contraction (Figure 1, top)
(2). ET-1 is the most potent, and perhaps the most pathophysiologically important,
vasoconstrictor reported to date. It is expressed as a propeptide by endothelial cells and is
activated by proteolytic cleavage mediated by ET-converting enzyme (40). Multiple
atherogenic factors induce ET-1, including lipoproteins, IFNγ, TNFα, thrombin and shear
stress (42–45). Aberrant expression of endothelial-derived ET-1 may function in a
number of vascular diseases, including atherosclerosis, where it is expressed in
atherosclerotic vessels and contributes to pathophysiological vasoconstriction (46–48).
Under normal conditions, the endothelium actively participates in the prevention
of blood clot formation. This non-thrombogenic property is maintained by the production
of several endothelial-derived factors that act on platelets and enzymes of the coagulation
cascade. Endothelial cells synthesize thrombomodulin which binds to thrombin and
inactivates thrombin’s procoagulant activity (2, 49, 50). Additionally, endothelial cells
synthesize the arachadonic acid metabolite prostacyclin (51), which was previously
discussed in terms of its role as a vasodilator. Prostacyclin is a particularly potent
inhibitor of platelet aggregation and platelet adherence to the endothelium (52, 53).
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Under

physiological

conditions,

endothelial-derived

prostacyclin

activates

the

prostacyclin receptor IP1 on platelets to inhibit aggregation and adhesion (54, 55).
Endothelial production of prostacyclin, thrombomodulin, and other anticoagulant
factors appears to be constitutive under physiological conditions, necessitating the rapid
production of the procoagulant factors when clotting is required. Endothelial cells
synthesize numerous thrombotic factors including tissue factor (TF) (56, 57), platelet
activating factor (PAF) (58, 59), factor VIII (60), and von Willebrand factor (vWF) (61).
TF is particularly important for the transformation of the vessel wall into a thrombogenic
surface because it promotes the activation of factors IX and X of the coagulation cascade
(1). Healthy vessels maintain a strict balance between thrombotic and anti-thrombotic
factors, favoring the expression of anti-thrombotic factors under physiological conditions,
and rapidly producing TF and other pro-coagulant factors following exposure to
thrombotic stimuli (Figure 1, right) (2). Endothelial expression of the pro-thrombotic TF
is induced by a variety of stimuli including thrombin, TNF, shear stress, and oxidized
lipoproteins (2, 6). Additionally, changes in the relative expression of tissue plasminogen
activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) contribute to increased
thrombogenicity of the activated endothelium. Activated endothelial cells tend to express
higher levels of PAI-1, which can be induced by oxidized lipoproteins and shear stress
(62–64) and lower levels of tPA (2, 65). Together, these changes reduce the rate of
fibrinolysis at localized sites of endothelial cell activation, creating a more thrombogenic
environment.
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1.1.3 Inflammatory Activation of the Endothelium
Under physiological conditions, the endothelium exists as a remarkably nonadhesive surface for circulating leukocytes. Various inflammatory agonists, including
TNFα, IL-1, thombin, and oxidized lipoproteins stimulate endothelial-leukocyte
interactions by inducing endothelial expression of leukocyte adhesion molecules (ELAM)
(3, 66–70). Leukocyte adhesion to the endothelium occurs in several steps. First,
circulating leukocytes are captured by endothelial-expressed selectin molecules (Eselectin, P-selectin), and “roll” along the luminal surface of the blood vessel. The next
step, firm adhesion, is mediated by adhesion molecules such as ICAM-1 and VCAM-1
that bind to leukocyte integrins and tether leukocytes to the endothelial surface.
Diapedesis and transendothelial migration of leukocytes occur due to a combination of
increased endothelial permeability and the expression of monocyte and T-cell
chemoattractants by endothelial and smooth muscle cells (2, 3, 71). These changes are
rapid and reversible in vivo. For example leukocyte rolling and adhesion is induced
within one hour of TNFα administration in mice, and this effect specifically requires
TNF receptors of the vascular endothelium, highlighting the important role of endothelial
activation in vascular inflammation (66).
Inflammatory stimuli that activate endothelial cells converge on several common
signaling pathways including NF-κB and MAPK signaling. The NF-κB family is
composed of five transcription factors, RelA (p65), RelB, c-Rel, NF-κB1 (p50), and NFκB2 (p52). In unstimulated cells, these proteins exist as latent cytoplasmic factors in
complex with inhibitors of NF-κB (IκBs) (72, 73). Inflammatory activation by TNF or
IL-1 causes rapid degradation of IκBs via the ubiquitin-proteosome system (74, 75),
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followed by translocation of NF-κB dimers to the nucleus where they bind to the
promoters of inflammatory genes, including ELAM and leukocyte chemoattractants, to
activate their transcription (3). MAPK signaling is also critical for inflammatory
activation of endothelial cells in response to cytokines. For example, p38 activity is
critical for induction of E-selectin and VCAM-1 in response to TNFα (68).
NF-κB signaling also regulates the formation and release of endothelial-derived
microparticles. Microparticles are membrane vesicles less than 1 µm in diameter that are
released from the cell in response to various stimuli. These microparticles can be
generated by the same agents that induce adhesion molecule and cytokine expression
(e.g., TNF and thrombin), and are functionally heterogenous (76). Depending on their
lipid and protein compositions, these NF-κB-regulated microparticles can be procoagulant, chemotactic, or promote leukocyte adhesion to the endothelium (77).
Circulating levels of endothelial-derived microparticles increase at early stages in
atherosclerosis and may contribute to disease progression, in part, by reducing eNOS
phosphorylation and the bioavailability of NO (77). The overall contribution of
microparticles to vascular disease progression remains uncertain. However, as a
functionally heterogenous group of bioactive substances, microparticles may represent an
additional target of pathophysiologically relevant factors regulated by NF-κB
transcription factors.

1.1.4 Growth-Factor Activation of the Endothelium and Angiogenesis
Normally quiescent under physiological conditions, endothelial cells can be
activated by growth factors to acquire proliferative, migratory, and invasive properties.
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Important stimulators of endothelial cell proliferation include fibroblast growth factor
(FGF), vascular endothelial growth factor (VEGF), PDGF, and epidermal growth factor
(EGF) (78). These substances also induce angiogenesis, the formation of new blood
vessels from the preexisting vasculature.
The primary event governing the initiation of angiogenesis is the formation of an
endothelial cell sprout from a preexisting endothelial cell monolayer (79). Environmental
cues, primarily in the form of growth-factors such as VEGF, stimulate quiescent
endothelial cells to become migratory and invasive (79, 80). This phenotypic change
coincides with a reduction in cell-to-cell contacts and a corresponding increase in
vascular permeability (80). Based on relative amounts of VEGF receptor-2 (VEGFR-2), a
“tip cell” (TC, high VEGFR-2 expression) is selected to lead an endothelial cell sprout to
form a new vessel (81). The TC leads migration by following chemoattractant guidance
cues and degrading extracellular matrix (ECM) proteins. Other activated endothelial
cells, termed “stalk cells,” (SC) follow behind TCs, maintain a proliferative phenotype,
and form a rudimentary new vessel lumen (Figure 1, top-right). Together, TCs and SCs
constitute the endothelial cell sprouts that continue to migrate until an adjacent sprout is
reached. Sprouts then fuse together in a process called anastomosis. Following
anastomosis, the motile and proliferative phenotypes of TCs and SCs are gradually lost,
and cell-to-cell junctions are reestablished to form a proper lumen and allow for blood
flow. The endothelium plays an additional role in forming a mature neovasculature by
synthesizing and depositing ECM proteins, as well as synthesizing growth-factors like
PDGF which recruit pericytes to support the new vessel (79).
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Figure 1. Mechanisms of endothelial cell activation. Clockwise from the left: Blood vessels are
lined by a single cell-thick layer of endothelial cells surrounded by extracellular matrix proteins
and concentric layers of smooth muscle cells. Endothelial cells synthesize and secrete a variety of
growth-factors and vasoactive substances (top) to regulate smooth muscle cell growth, motility,
and vessel tone. Endothelial cells also respond to growth-factors to create angiogenic sprouts to
form new blood vessels (top right). Endothelial cells actively regulate the hemostatic/thrombotic
balance of circulating blood by modulating production of pro-coagulant and anti-coagulant
factors (right). Inflammatory activation of endothelial cells (bottom) is caused by a wide-variety
of factors and is implicated in numerous disease states, including atherosclerosis. Inflammatory
factors like TNF induce expression of leukocyte adhesion molecules and chemokines that recruit
leukocytes to sites of inflammation, permit leukocyte rolling and firm adhesion to endothelial
cells, and facilitate the extravasation of leukocytes into the subendothelial space. The
accumulation of monocytes in the subendothelial space, and the activation of monocytes by
oxidized lipoproteins and endothelial-derived factors is a critical event in the initiation of
atherosclerosis. (From Waitkus, Harris, and DiCorleto, “Mechanisms of Endothelial Activation”
in The Encyclopedia of Medical Immunology, 2014. ISBN 978-0-387-84827-3.)
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1.1.5 Significance of Endothelial Activation
As the body’s largest homeostatic organ, the vascular endothelium forms a
marvelous non-thrombogenic surface lining every vessel in the body. Its function is
critical for maintaining vascular health, and its dysfunction is associated with the genesis
and progression of various vascular diseases. As a dynamic biological interface, the
endothelium has the capacity to sense environmental changes, synthesize vasoactive
substances, interact with other cell-types, regulate vascular permeability, and form
collateral vessels from the preexisting vasculature. Dysregulation of these processes is
present in many vascular diseases, and endothelial dysfunction often precedes
atherosclerosis and associated conditions, suggesting that endothelial activation may play
a causative role in serious vascular illnesses.
Although the endothelium is known to participate in the genesis and progression
of vascular diseases, the specific triggering events of endothelial activation that
distinguish pathophysiological dysfunction from physiological adaptation are still
incompletely characterized. Therefore, a more thorough understanding of endothelial
dysfunction may lead to descriptions of causative events underlying endothelial
dysfunction for distinct disease states. Such knowledge may allow for better riskstratification of patients before major adverse events, as well as the identification of novel
opportunities for therapeutic intervention to prevent or treat vascular diseases.

1.2

Mechanisms of Thrombin Signaling through Protease-activated Receptors
Previous studies in our laboratory have focused on the actions of thrombin in

regulating inflammatory activation of vascular endothelial cells (67, 68, 82–84).
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Thrombin is well known for its role in regulating blood coagulation, but it also activates a
family of receptors termed protease-activated receptors (PARs) to initiate intracellular
signaling pathways in numerous cell types (85). In this way, PARs critically link the
process of thrombin generation following tissue injury to injury-induced cellular
responses via activation of cell surface receptors. Further, thrombin-dependent activation
of PAR-1 on endothelial cells is a potent inducer of endothelial-leukocyte adhesion
molecules (ELAM), and may therefore provide a link between tissue injury and
inflammation.

1.2.1 Structure and Function of Protease-activated Receptors
The PARs are members of the family of G-protein coupled receptors (GPCRs)
that comprises the largest class of transmembrane signaling proteins in the human
genome (86). GPCRs have an extracellular NH2-terminus, seven distinct transmembrane
helices with alternating intracellular and extracellular “loop” regions, and an intracellular
COOH-terminus (Figure 2). For most GPCRs, ligand binding to an extracellular pocket
formed by the transmembrane helices causes conformational changes in the receptor that
activate heterotrimeric G-proteins via nucleotide exchange. By this mechanism, GPCRs
act as transmembrane guanine nucleotide exchange factors (GEF) that trigger GDP-GTP
exchange and activation of G-proteins when the appropriate extracellular cue is present.
PARs are a unique among GPCRs because they are irreversibly activated via
protease-mediated cleavage of their NH2-terminus (87). Thrombin cleaves a 41 amino
acid domain (Figure 2, red) from the NH2-terminus of PAR-1, thus exposing a new NH2terminus (Figure 2, blue). The newly exposed NH2-terminal domain acts as a tethered
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ligand by binding to the second extracellular loop of PAR-1 to activate G-proteindependent signaling (Figure 2, right) (88). A peptide agonist composed of the sequence
Ser-Phe-Leu-Leu-Arg-Asn, termed thrombin-receptor agonist peptide (TRAP), that
corresponds to the newly exposed NH2-terminus of PAR-1 can activate PAR-1-dependent
signaling pathways independent of receptor cleavage (89, 90).

Figure 2. PAR-1 Activation by Thrombin. Thrombin cleaves a 41 amino acid sequence of the
PAR-1 NH2-terminus (shown in red). Following cleavage, the newly generated NH2-terminus acts
as a tethered ligand by binding to the extracellular domain of PAR-1 and activating intracellular
signaling pathways.

PAR-1 can be activated by several proteases including thrombin, TF-VIIa-Xa,
activated-Protein C, plasmin, MMP-1 (90–95). Cleaved and activated PAR-1 couples to
the G-protein subunits Gα12, Gα13, Gαq, GαI, and Gβγ (85, 96, 97), and activates a
15

multitude of signaling pathways including MAPKs, Src family kinases, PI3K-AKT,
phospholipase C, Rho-associated protein kinases, and transactivation of receptor tyrosine
kinases (68, 82, 98–103). Through these signaling pathways, thrombin transduces the
information of tissue injury to generate the appropriate cellular responses of
inflammation, proliferation, and cellular migration (67, 102, 104, 105).

1.2.2 Thrombin-activated Signaling Pathways in Endothelial Cells
Endothelial cells line the luminal surface of the vasculature and are exposed to
thrombin following tissue injury. Endothelial cells predominantly express PAR-1, and
exposure to thrombin stimulates multiple PAR-1-dependent signaling pathways including
activation of MAPKs and Src family kinases (68, 106). Activation of endothelial PAR-1
by thrombin induces expression of leukocyte adhesion molecules (68, 84) and leukocyte
adhesion to an endothelial monolayer (67, 82). Further, thrombin stimulates angiogenesis
and endothelial cell migration by directly activating endothelial PAR-1 (84). Kinney et al.
showed that thrombin induces ex vivo endothelial cell sprouting from murine aortic rings
(106), and

others have shown that low levels of thrombin induce endothelial

differentiation into tube-like structures on a basement membrane extract (105).
These results are largely consistent with earlier observations that exogenous
thrombin or TRAP administration enhances wound healing and neovascularization of
dorsal incisions in rats (107). In contrast, Connolly et al. reported that PAR-1 knockout
mice did not have significantly altered wound healing responses compared to wild-type
littermates (108). However, the same laboratory and others also reported that ~50% of
PAR-1 deficient mice die at embryonic day 9.5, likely due to severe defects in the
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development of yolk sac vasculature (109–111). Another report demonstrated that PAR-1
knockout mice displayed altered vascular remodeling following arterial injury, and that
PAR-1-deficient mice did not show injury-induced increases in vessel and lumen
diameters that were observed in wild-type mice (112).
Collectively, existing literature suggests that thrombin-dependent activation of
PAR-1 increases localized inflammation, facilitates neovascularization following injury,
and increases cellular proliferation and migration. The fact that ~50% of PAR-1-/embryos die at ~E9.5 suggests that PAR-1-dependent processes, particularly
vascularization, are critical for normal development. The elucidation of novel PAR-1
signaling mechanisms may therefore reveal unappreciated therapeutic opportunities to
enhance wound healing and neovascularization following tissue injury, as these processes
are limiting factors that regulate the regeneration of functional tissues. Furthermore,
aberrant thrombin generation in advanced cancers creates a hypercoagulable state that
contributes to tumor-associated angiogenesis and metastasis (113). Therefore,
understanding mechanisms by which thrombin/PAR-1 signaling cooperates with
oncogenic signaling pathways, including EGFR and STAT3, may reveal novel aspects of
the tumor microenvironment that facilitate tumor vascularization, growth, and metastasis.

1.3

Mechanisms of EGF Receptor Signaling
The EGF receptor (EGFR) is a member of the ErbB family of RTKs that includes

HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. The ErbB receptors are single-pass
transmembrane receptors with extracellular ligand binding domains, a transmembrane
domain, and a cytosolic tail with a tyrosine kinase domain (Figure 3). The four receptors
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form a variety of homodimers and heterodimers in response to the EGF family of ligands.
EGFR, HER3, and HER4 directly respond to a number of EGF family members (Figure
3). Some of these ligands bind multiple family members (HB-EGF), while others are
specific to a single receptor (EGF). To date, there is no known ligand for HER2 (114).
Structurally, HER2 is constitutively in an “open” state, poised for dimerization, but does
not readily homodimerize (115, 116). Instead, HER2 forms functional heterodimers with
other ErbB family members to initiate intracellular signaling cascades (114).

Figure 3. The ErbB family of receptors and their ligands. ErbB receptors can be activated by
numerous endogenous ligands. Binding of a ligand to a receptor facilitates homo- and heterodimerization, autophosphorylation, and activates downstream signaling pathways including
MAPK and AKT signaling.

EGFR is activated by EGF, HB-EGF, TGFα, betacellulin, epiregulin, epigen, and
amphiregulin (117). In the absence of these ligands, EGFR is predominantly in a “closed”
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conformation in which contacts between extracellular domain II and IV sequester the
dimerization arm from other receptors (118). Ligand-binding to extracellular domains I
and III of EGFR causes EGFR to adopt an “open” conformation in which the
dimerization arm is exposed (Figure 4) (118). In this ligand-bound conformation, EGFR
readily forms homodimers or heterodimers with HER2 (114, 116). Intracellularly,
dimerization facilitates physical association of the cytosolic tails of EGFR monomers.
Multiple lines of evidence suggest that the active state involves one monomer acting as
an allosteric activator for the kinase domain of the other monomer, creating an
asymmetric dimer in which only one kinase domain is activated (119, 120). The active
kinase domain of one monomer transphosphorylates the other, and the resulting
phosphotyrosine residues of EGFR cytosolic tail act as binding sites for adaptor protein
with SH2 or phosphotyrosine-binding domains (114, 121). These adaptor proteins
activate numerous intracellular signaling cascades that ultimately elicit changes in gene
expression and cellular phenotypes.
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Figure 4. Mechanism of ligand-mediated EGFR dimerization. Ligand binding causes EGFR
monomers to adopt an “open” conformation in which the dimerization arm of the second
extracellular domain is extended. Dimerization leads to kinase activation and phosphorylation of
tyrosine residues in the EGFR cytosolic tail.

1.3.1 Overview of EGF Receptor Signaling Pathways
EGFR activation initiates a number of signaling pathways including MAPK,
PI3K, Src-family kinases, NF-κB, and STATs (122–125). Several phosphotyrosine
residues on the EGFR cytosolic tail act as binding sites for the adaptor protein Grb2
which, in turn, initiates the canonical pathway of MAPK activation via RAS and RAF.
Further, EGF induces STAT3 Tyr705 phosphorylation (123), and this pathway may play a
role in oncogenesis and drug resistance in head and neck squamous cell carcinoma (126).
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Recently, Guo and Stark reported that EGFR induces NF-κB activation by a mechanism
that requires the tyrosine kinase Fer in lung cancer cells (124).
In 1996, Daub et al. observed that activation of GPCRs rapidly leads to the
phosphorylation of EGFR and Neu (HER2 ortholog) and termed this phenomenon
“transactivation” (127).

Prenzel et al. subsequently determined that EGFR

transactivation by LPA or carbachol required metalloprotease-mediated cleavage of HBEGF (100). By this mechanism, GPCR activation leads to autocrine activation of RTKs
such as EGFR, thus facilitating a type of cellular crosstalk between cell surface receptors
(Figure 5). These studies formed the basis for a large number of subsequent
investigations of GPCR-mediated transactivation of EGFR. Transactivation of EGFR
functions in diverse cellular processes including proliferation, migration, and invasion
(128–130).
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Figure 5. GPCR-mediated transactivation of EGFR. Activation of GPCRs such as PAR-1
activated MMPs that, in turn, cleave and release growth-factors from their pro-peptide precursors.
Released growth factors (e.g. HB-EGF can activate EGFR in an autocrine fashion.

1.3.2 Endothelial EGF Receptor Signaling
EGF was first shown to increase the rate of endothelial cell proliferation by
Gospodarowicz et al. in 1978 (131). In this study, EGF increased the proliferative
response of human endothelial cells, but not bovine endothelial cells, in the presence of
calf serum. Further, the EGF-induced proliferative response was potentiated by
simultaneous stimulation with thrombin, indicating some interaction between EGF and
thrombin-activated signaling pathways. A subsequent study by a different group
reproduced the effects of EGF on HUVEC, but was unable to reproduce the potentiation
of EGF-dependent proliferation by thrombin (132).
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Given its capacity to stimulate cell proliferation, EGF was investigated for its
ability to enhance corneal endothelial cell proliferation, migration, and wound closure.
EGF was found to be a potent inducer of corneal endothelial cell migration in mitotically
inhibited corneal endothelial cells (133). A subsequent study demonstrated that EGF
administration increased the rate of endothelial wound closure in excised corneas (134).
Furthermore, both EGF and TGFα, an EGF family member, were found to induce
angiogenesis in vivo (135). These results suggested that EGF is an endogenous inducer of
angiogenesis and wound closure, and could potentially act as a therapeutic agent to
stimulate tissue regeneration.
Studies throughout the 1980s and 1990s characterized the binding of EGF to
various endothelial cells from different species, as well as the proliferative and migratory
response to EGF by these cells. However, more recent studies presented evidence that
EGFR was not expressed on either MVEC (136) or HUVEC (136–139). It is important to
note that these studies predominantly relied on immunoblot analyses to assess endothelial
EGFR expression, and, in at least two cases, compared EGFR expression in endothelial
cells to cancer cell lines with overexpression of EGFR (136). Earlier studies employed
radioligand binding assays of EGF to endothelial cells to identify EGF-EGFR binding,
and it is likely that the superior sensitivity of radioligand binding assays relative to
immunoblots is one of the reasons for the conflicting reports of endothelial EGFR
expression in the literature.
We have reported that EGF induces HUVEC migration in vitro, in contrast to the
results of others (84, 137). Another group performed a direct comparison of EGF and
VEGF-induced

angiogenesis

in

vivo,

and
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demonstrated

that

EGF

induces

neovascularization to the same extent as VEGF in the mouse cornea (140). Mehta et al.
reported that activation of EGFR by HB-EGF induces HUVEC migration and tube
formation via the MAPK and PI3K pathways (141). More recently, Maretzky et al. found
that VEGF-induced endothelial cell migration requires EGFR activity, suggesting that
there exists some degree of crosstalk between these major vascular signaling pathways
(142). These results suggest that endothelial EGFR function is an important and
understudied regulator of endothelial cell physiology, and may significantly contribute to
postnatal angiogenesis in vivo. It is therefore critical to improve our knowledge of
endothelial EGFR functions so that we may begin to understand the extent to which
endothelial EGFR signaling contributes to vascular physiology and disease.
Given its anatomic location, the endothelium is constantly exposed to a variety of
disparate stimuli within the vascular microenvironment. Consequently, endothelial cells
not only respond to specific agonists per se, but also integrate different, potentially
conflicting, signals and formulate appropriate biological responses to maintain vascular
health. Signal transduction cascades are well defined with regard single ligand/receptor
models, but less is known about how endothelial cells respond when they are exposed to
multiple stimuli simultaneously. Importantly, previously published results from our
laboratory suggest that simultaneous exposure of endothelial cells to EGF and thrombin
triggers synergistic induction of immediate early genes, but the mechanism of signal
integration is unknown.
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1.4

Mechanisms of STAT3 Activation
Named for its dual role as a signal transducer and transcription factor (143),

STAT3 is a highly studied protein that regulates numerous physiological processes (e.g.
angiogenesis, oncogenesis). This chapter will provide a brief summary of the discovery
and characterization of STAT transcription factors, with a specific focus on STAT3. A
detailed review of STAT3 literature will follow that summarizes the complex regulatory
mechanisms that exist for modulating STAT3 activity in a diverse set of
microenvironments. This review will therefore provide a proper context with which to
understand the results of our STAT3 studies, and will ultimately highlight the novelty of
our results and the extent to which they enhance the fundamental understanding of
STAT3 biology.

1.4.1 The Discovery of STATs
The discovery of STAT transcription factors was primarily the result of work in
the laboratory of Dr. James E. Darnell Jr. that focused on identifying DNA-binding
proteins that bound specific IFN-stimulated response elements (ISREs) in the promoters
of IFN α/β-responsive genes. Studies from the Darnell lab revealed that promoters of the
IFN-inducible genes IFIT2 (ISG54) and ISG15 contained a conserved DNA element
~100 base pairs upstream from the transcription initiation start site (144, 145). By using
this DNA element as a probe, Levy et al. were able to detect binding of a large protein
complex, termed ISGF3, to the ISRE in the 5’ region of IFIT2 (146). Subsequent work by
Xin-Yuan Fu revealed that ISGF3 is composed of four distinct proteins with masses of
113, 91, 84, and 48 kDa (147). These proteins formed a multisubunit complex that
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coimmunoprecipitated with anti-sera against the 113 or 91 kDa protein (148).
Furthermore, it was observed that the 91 kDa subunit of ISGF3 also mediated activation
of IFN-γ-dependent genes by binding to distinct DNA sequences termed GAS elements
(gamma-IFN-activated site) in the promoters of IFN-γ-responsive genes (149, 150).
Tyrosine kinase inhibitors, but not a broad-spectrum serine kinase inhibitor, prevented
ISGF3 formation in response to IFN-α, and the 91 kDa protein that bound to GAS
elements was found to be phosphorylated at Tyr701 (151, 152), suggesting that inducible
phosphorylation was critical for activity of these transcription factors. The 91 kDa protein
was termed STAT1 (signal transducer and activator of transcription 1), named for its dual
role as a signal transducer and transcription factor in response to IFNs (143).
Shortly after the discoveries that uncovered STAT1 activation in response to
IFNs, STAT3 and STAT4 were cloned from a cDNA library by Zhong et al. in the
Darnell laboratory (153). Over a short period of time, multiple labs working in parallel
discovered that STAT3 is activated by IL-6 or EGF via tyrosine phosphorylation, and that
STAT3 binds to GAS elements in the promoters of IFNγ-inducible genes (123, 154, 155).
These studies revealed that STAT1 and STAT3 were similar, but functionally distinct
members of a larger family of transcription factors, and raised important questions
regarding the specificity of STAT3 activation, as well as the significance of STAT3mediated transcription.

1.4.2 Canonical STAT3 Signaling Mechanisms
Original studies of STAT3 signaling found that IL-6 or EGF treatment causes
rapid phosphorylation of STAT3 at Tyr705 (123). This phosphorylation coincides with
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formation of STAT3 homodimers and STAT1-STAT3 heterodimers that bind to GAS
elements. However, the exact mechanisms regulating Tyr705 phosphorylation and the
kinases involved remained unclear after these initial reports. Janus kinases (JAKs) were
known to regulate interferon signaling (143), and it was found that JAK1 was rapidly
tyrosine phosphorylated in response to IL-6 (156). Both STAT3 and JAK1 physically
associated with the signal transduction protein gp130 upon IL-6 stimulation, suggesting
that there was a direct link between JAK1 and STAT3 phosphorylation. Indeed,
subsequent studies demonstrated that human fibrosarcoma cells lacking JAK1 exhibited
remarkably reduced STAT3 phosphorylation in response to IL-6 (157). The same study
found that JAK2 and TYK2 are also activated in response to IL-6, but are insufficient for
STAT3 tyrosine phosphorylation, demonstrating a critical and non-redundant role for
JAK1 in STAT3 Tyr705 phosphorylation.
Shortly after the JAK1-STAT3 connection was established, STAT3 was found to
have a second site of phosphorylation that was sensitive to H7 kinase inhibitors (158).
This site was determined to be a serine phosphorylation, and Wen et al. found that
phosphorylation at this site was critical for maximal transcriptional activity of STAT3
(159). STAT3 serine phosphorylation was subsequently mapped to Ser727, and was found
to have no effect on STAT3 DNA-binding activity (160). Additional studies found that
Ser727 phosphorylation was critical for STAT3-dependent gene induction in response to
IL-6 and OSM (161). Importantly, a study by Shen et al. showed that mice with only one
wild-type STAT3 allele (WT/-) develop normally, but ~75% of mice with one STAT3
mutant allele, where Ser727 was mutated to alanine (S727A/-), die perinatally (162).
Embryonic fibroblasts from the S727A/- mice exhibited a reduced transcriptional
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response to OSM, demonstrating that STAT3 transcriptional activity is critical for proper
development and is likely modulated by Ser727 phosphorylation in vivo. Mechanistically,
there is ample evidence to suggest that Ser727 phosphorylation acts as a phosphoserine
binding site for transcriptional coactivators such as p300 (161, 163).
More recently, several other posttranslational modifications have been discovered
on STAT3 including arginine and lysine methylation, lysine acetylation, and threonine
phosphorylation (Figure 6). Yang et al. reported that IL-6 induces STAT3 Lys140
methylation, and that this modification increases or decreases STAT3 transcriptional
activity in a gene-specific manner (164). The protein arginine methyltransferase 2
(PRMT2) methylates STAT3 at Arg31, and this modification is a negative regulator of
leptin signaling (165). Various sites of lysine acetylation of STAT3 have also been
reported (166–169), and it is believed that acetylation of Lys685 by p300 regulates STAT3
dimerization (167). STAT3 Thr714 phosphorylation has been identified in several
phosphoproteomic studies (170–172), but site-specific studies have not been pursued and
proximal kinases for this modification are unknown.
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Figure 6. Map of STAT3 posttranslational modifications. STAT3 domains are color-coded
and labeled below the map (TAD, transactivation domain). STAT3 is posttranslationally modified
at multiple sites. These modifications include arginine methylation (meR), lysine methylation
(meK), acetyl-lysine (aK), phosphotyrosine (pY), phosphothreonine (pT), and phosphoserine
(pS).

Taken together, these results suggest that numerous STAT3 PTMs cooperate to
regulate STAT3 transcriptional activity. Although it is clear that regulation of STAT3
function is more complex than simply regulating Tyr705 phosphorylation, the overall
model of Tyr705 phosphorylation and dimerization as the major driver of STAT3 activity
has persisted. More recently, however, alternative mechanisms of STAT3 activation that
do not require Tyr705 phosphorylation have been discovered and characterized.

1.4.3 Alternative Mechanisms of STAT3 Activation
Recent progress in the STAT3 field has made it increasingly clear that Tyr705
phosphorylation is not an absolute requirement for STAT3-mediated gene expression. In
fact, multiple laboratories have reported STAT3 functions that occur in the absence of
Tyr705 phosphorylation including cooperation with the NF-κB subunit p65 (173),
phosphorylation-independent dimerization and DNA-binding (174–176), and regulation
of cellular respiration in mitochondria (177, 178). These results demonstrate the
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complexity of STAT3 regulation and suggest that a wide range of previously unreported
noncanonical STAT3 functions may exist.
STAT3 positively regulates the expression of its own gene by binding to its
promoter and increasing STAT3 transcription (179, 180). While stimulus-dependent
increases in Tyr705 phosphorylation return to basal levels relatively quickly, the elevated
levels of tyrosine-unphosphorylated STAT3 (U-STAT3) may persist for hours after
cytokine stimulation (181). U-STAT3 competes with IκB for p65-binding in the
cytoplasm, and high levels of U-STAT3 eventually lead to p65-STAT3 complex
formation. This protein complex drives gene expression by binding the promoters of
genes with κB elements, including RANTES (181). Others have shown that U-STAT3 and
NF-κB cooperate to increase expression of serum amyloid A (SAA) after cells are
simultaneously treated with IL-1 and IL-6 (173). These reports demonstrate that USTAT3 drives gene expression in a manner that is distinct from canonical IL-6/JAKdependent mechanisms. Importantly, these mechanisms highlight the interaction of
STAT3 and NF-κB signaling, and reveal an underlying combinatorial complexity of
processes that control STAT3 activation.
U-STAT3 has also been shown to dimerize and bind DNA in the absence of NFκB subunits. Braunstein et al. first made the unexpected observation that STAT1 and
STAT3 form stable homodimers in the absence of tyrosine phosphorylation (174).
Although the U-STAT dimers were stable in unstimulated cells, they did not possess
DNA-binding activity, suggesting that an additional regulatory mechanism must exist to
modulate STAT3 DNA-binding. More recently, Timofeeva et al. used atomic force
microscopy to examine the binding of U-STAT3 to GAS elements (175). They found that
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U-STAT3 binds to GAS elements as dimers or monomers. Further, it was observed that
U-STAT3 binds to AT-rich DNA elements as well as cruciform structures in DNA,
suggesting that numerous DNA elements may be targets of U-STAT3 signaling. More
recently, a crystal structure of U-STAT3 binding to DNA has been published,
demonstrating that U-STAT3 dimers bind to GAS elements in a structurally similar
manner to Tyr705-phosphorylated STAT3 (176).
These alternative, Tyr705-independent mechanisms of STAT3 activation led Yang
and Stark to speculate (179) that ancestral STAT3 functions may have existed without
tyrosine phosphorylation, and that ligand-dependent STAT3 activation is a more recently
evolved process. If this is indeed the case, it stands to reason that numerous alternative
mechanisms of ligand-dependent STAT3 activation may have evolved in parallel with
JAK-STAT3 signaling.

1.4.4 Dysregulation of STAT3 Signaling in Disease
STAT3 controls the expression of genes regulating cell growth, survival, and
wound healing (182–185). Additionally, STAT3 is aberrantly activated in a majority of
human cancers and drives pathological angiogenesis by positively regulating VEGF-A
expression (185). Importantly, there are several reports that demonstrate STAT3 plays a
role in cancer progression in the absence of Tyr705 phosphorylation (186–188).
Collectively, these reports suggest that STAT3 is a viable target for anti-cancer therapy,
and that multiple, independent mechanisms of STAT3 activation should be considered
when designing STAT3-targeted therapies.
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The importance of STAT3 activation in cancer was first realized when it was
observed that v-Src overexpression causes constitutive phosphorylation of STAT3 at
Tyr705 (189). Subsequent studies found that STAT3 is required for v-Src induced
transformation of fibroblasts (190, 191). In a series of experiments, it became clear that
STAT3 is a central mediator of cellular transformation, as overexpression of various
oncogenes leads to constitutive STAT3 activation (192), and numerous signaling
pathways cooperate to maximize the full transformative potential of STAT3 (193–196).
These initial experiments focused on Tyr705 phosphorylation as an indicator of
STAT3 activity in cancer. This was a natural endpoint for analyzing STAT3 activation,
as the JAK-STAT pathway was relatively well characterized at the time (143).
Importantly, subsequent work found that oncogenic kinases that are frequently mutated in
human malignancies, including EGFR, JAK2, and ALK induce STAT3 Tyr705
phosphorylation, STAT3 target gene expression, and cancer cell proliferation (197–202).
Genomic alterations of EGFR, including the constitutively active EGFRvIII mutants and
an EGFR-SEPT14 gene fusion, also cause STAT3 activation via Tyr705 phosphorylation
and drive oncogenesis, proliferation, and cellular invasion in various forms of cancer
(203–207). Furthermore, STAT3 Tyr705 is found in a subset of patients with clear cell and
papillary renal cell carcinomas (208), and inhibition of STAT3 activity significantly
slows growth of xenograft renal tumors in a mouse model (209). These results
demonstrate that STAT3 activation via Tyr705 phosphorylation positively regulates
oncogenesis and tumor growth, making it a strong candidate for targeted anti-cancer
therapy.
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STAT3 has also been shown to regulate target gene expression, cell survival, and
proliferation in the absence of Tyr705 phosphorylation. This observation is consistent with
the previously discussed roles of U-STAT3 in transcriptional regulation, as well as the
ability of U-STAT3 to dimerize, bind GAS elements, and cooperate with NF-κB family
members (174, 175, 179). Liu et al. first showed that Ser727-phosphorylated STAT3
drives expression of Mcl1 in macrophages in the absence of detectable Tyr705
phosphorylation (187). Yang et al. reported that overexpressing a STAT Y705F mutant
activated the expression of many target genes including EGFR, MET, and MRAS (210).
Ng et al. found that STAT3 that is Ser727-phosphorylated, but not Tyr705-phosphorylated,
regulated NGF-dependent gene expression in PC12 cells (211). Further, U-STAT3 is
induced in response to IL-6, binds to NF-κB, and activates a set of genes that are not
directly activated by P-STAT3 including RANTES, MET, IL-8, and IL-6 (181). In human
prostate cancer cells, a Ser727 phosphomimetic STAT3 mutant (S727E) is capable of
driving cellular growth and tumor formation in mice (188). Further, tumors harboring a
S727E/Y705F STAT3 double mutant did not show reduced tumorigenesis or
invasiveness, and the degree of Ser727 phosphorylation correlated with Gleason score of
human prostate cancer tissue in the study (188). These results conclusively demonstrated
that STAT3 is activated in the absence of Tyr705 phosphorylation in a manner that drives
tumor growth and invasion in vivo. In agreement with these findings, a more recent report
demonstrated that STAT3 is constitutively phosphorylated at Ser727 in patients with
chronic lymphocytic leukemia (CLL) and can bind DNA in the absence of Tyr705
phosphorylation (186). The researchers also found that inhibition of STAT3 in patient
CLL cells reduced expression of STAT3 target genes and induced apoptosis, suggesting
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that Ser727-phosphorylated STAT3 can be targeted in human malignancies to inhibit
disease progression (186).

The canonical pathway of JAK-STAT signaling originally put forth by Darnell,
Kerr, and Stark (212) has been shown to participate in numerous cellular processes
including immunity, angiogenesis, and oncogenesis (143).

However, it has become

increasingly clear that there exist alternative mechanisms of STAT3 activation that do not
require Tyr705 phosphorylation. The full repertoire of molecular mechanisms governing
STAT3 function likely includes an astoundingly complex combination of U-STAT3,
Ser727-phosphorylated STAT3, cooperation with NF-κB family members, and binding to
various DNA elements including GAS, κB, and AT-rich elements to modulate
transcription.
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2.1

Abstract
Signaling pathways interact with one another to form dynamic networks in which

the cellular response to one stimulus may depend on the presence, intensity, timing, or
localization of other signals. In rare cases, two stimuli may be simultaneously required
for cells to elicit a significant biological output. This phenomenon, generally termed
“coincidence detection,” requires a downstream signaling node that functions as a
Boolean AND gate to restrict biological output from a network unless multiple stimuli
are received within a specific window of time. Simultaneous activation of EGF receptor
(EGFR) and a thrombin receptor (protease-activated receptor-1, PAR-1) increases the
expression of multiple immediate early genes (IEGs) associated with growth and
angiogenesis. Using a bioinformatic comparison of IEG promoter regions, we identified
STAT3 as a critical transcription factor for the detection of coincident EGFR/PAR-1
activation. EGFR activation induces classical STAT3 Tyr705 phosphorylation but also
initiates an inhibitory signal through the PI3K-AKT signaling axis that prevents STAT3
Ser727 phosphorylation. Coincident PAR-1 signaling resolves these conflicting, EGFactivated pathways by blocking AKT activation and permitting GSK-3α/β-dependent
STAT3 Ser727 phosphorylation and STAT3-dependent gene expression. Functionally,
combinatorial EGFR/PAR-1 signaling suppresses EGF-induced proliferation and
thrombin-induced leukocyte adhesion and triggers a STAT3-dependent increase in
endothelial cell migration. This study reveals a novel signaling role for STAT3 in which
the simultaneous presence of extracellular EGF and thrombin is detected at the level of
STAT3 post-translational modifications. Collectively, our results describe a novel
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regulatory mechanism in which combinatorial EGFR/PAR-1 signaling regulates STAT3dependent IEG induction and endothelial cell migration.

2.2

Introduction
Cell-type and spatiotemporal signaling contexts are critical determining factors

for the propagation of signaling cascades from cell surface receptors (213). Rather than
having defined pathways of signaling, receptors may activate unique complements of
pathways depending on the presence, intensity, timing, or localization of other signals
(213, 214). This nuanced view of cellular signaling requires integration of multivariate
extracellular information via coordinated crosstalk between signaling pathways. In this
manner, signaling interactions enable cells to process disparate extracellular information
at downstream signaling nodes and formulate appropriate biological responses based on
specific combinations of signaling inputs (121, 215). Crosstalk is an important factor in a
number of biological processes including cellular migration (142), proliferation (128),
gene expression (84, 216), and calcium influx (215). However, the specific molecular
mechanisms by which cells integrate signals from multiple cell surface receptors are
poorly understood (213).
In many cases, the output of signaling interactions is merely the sum of individual
signaling inputs. Less often, multiple signaling inputs induce moderate synergisms of
phosphorylation, calcium influx, or gene expression. In rare cases, however,
simultaneous signals may induce marked synergisms, where the response to combined
stimuli is far greater than the sum of responses to individual inputs (215). This type of
superadditive response can be expressed quantitatively as a synergism ratio (SR)1 and

37

calculated by dividing the response to combined stimulation by the sum of individual
responses. As SR increases, signaling interactions begin to function as cellular
coincidence detectors, where simultaneous stimuli are required for cells to elicit a
significant biological response. Coincidence detection may occur by several mechanisms
including multiple phosphorylation events (217), cooperative binding of regulatory
molecules (218),

multivalent binding of modular protein domains (219), two-state

allosteric regulation (220), protein scaffolding (221), and simultaneous alterations in
relative activity between antagonistic enzymes (e.g. phosphatase/kinase) (216, 222).
Much research has focused on signaling interactions between G-protein coupled
receptors (GPCRs) and receptor tyrosine kinases (RTKs) (223). The classical model of
RTK/GPCR

crosstalk

involves

GPCR-mediated

transactivation

of

RTKs

via

metalloprotease-mediated cleavage of membrane-bound growth-factor precursors and
subsequent autocrine activation of RTKs (100). Although this model of RTK/GPCR
interactions constitutes a crosstalk between cell surface receptors, it only describes a form
of linear information transfer where an RTK is essentially a downstream effector of
GPCR signaling. As such, this model does not address mechanisms by which intracellular
pathways integrate extracellular information following coincident activation of RTKs and
GPCRs.
Previous work in our lab focused on a RTK/GPCR interaction in endothelial cells
(EC) involving the epidermal growth factor (EGF) receptor and the thrombin receptor,
protease-activated receptor-1 (PAR-1) (84). EC are situated in direct contact with the
bloodstream and are constantly exposed to a wide variety of stimuli including growth
factors, hormones, biomechanical forces, microbial pathogens, and inflammatory agents.
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Responses to these stimuli are mediated, at least in part, by the induction of immediate
early genes (IEGs). As a family of transcription factors, cytokines, phosphatases, and
other enzymes, IEGs are important determinants of delayed gene expression and
phenotypic outcomes (224, 225). We previously reported that simultaneous exposure of
EC to EGF and thrombin caused a synergistic induction of the IEG mitogen-activated
protein kinase phosphatase-1 (MKP-1) and enhanced migration of EC in vitro (84). EGF
is a well-known stimulator of cell growth and induces EC proliferation, migration, and
angiogenesis (226). Thrombin is a serine protease that regulates blood coagulation, but
also acts as a signaling molecule by cleaving the NH2-terminus of protease-activated
receptors (PARs). We previously showed that synergistic induction of MKP-1 by EGF
and thrombin was mediated specifically by PAR-1 activation (84). An increased
understanding of signaling interactions between EGFR and PAR-1 may yield valuable
insight into the mechanisms by which EC signaling networks integrate multivariate
extracellular information in pathological microenvironments.
In this report, we describe a detailed, novel molecular mechanism of EGFR/PAR1 crosstalk. We show that STAT3 is a critical point of convergence of signals from EGFR
and PAR-1, and functions as a cellular coincidence detector to enhance IEG expression
following simultaneous EGFR/PAR-1 activation. Importantly, combinatorial receptor
signaling coincides with a suppression of EGF-induced proliferation and thrombininduced leukocyte adhesion, and causes a STAT3-dependent enhancement of EC
migration. Combinatorial activation of STAT3 is therefore a critical event for increasing
the magnitude of IEG expression, and plays an important role in determining the ultimate
phenotypic response of EC during simultaneous exposure to disparate signaling inputs.
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2.3

Materials And Methods
Cell-Culture, Transfections, and Treatments. Human EC were isolated by

trypsinization of umbilical veins as previously described (67). EC were plated on
fibronectin coated cell-culture dishes and maintained in MCDB/F12 media containing
15% FBS, .009% heparin, and .015% endothelial cell growth supplement. All
experiments were carried out using cells between the third and fifth passage. EC were
transfected using Targefect reagents (Targeting Systems) according to the manufacturer’s
protocol. Unless otherwise indicated, EC were serum-starved for 2 hours prior to
treatment with EGF (16 ng/ml), TRAP (100 µM), or thrombin (5U/ml).

Generation of EGR1 Promoter Luciferase Reporter and Luciferase Assay. A
2.1 kb fragment of the EGR1 promoter was PCR amplified (See Table VIII for primers)
from human genomic DNA. The fragment spanned from -1958 bp upstream of the EGR1
transcription initiation site to +160 bp into the first exon (Figure 61), and was cloned into
pGL3-Basic firefly luciferase reporter between the MluI and BglII restriction sites. Site
directed mutagenesis of the EGR1 promoter distal GAS element (TTCCCGGAA !
gcgCCGGAA) and proximal GAS element (TTCCCCGAA ! gcgCCCGAA) was
performed using the GeneArt site-directed mutagenesis kit (Invitrogen) according to the
manufacturer’s instructions. Luciferase assays were performed by transfecting EC with
EGR1-Promoter reporter 24 hours prior to treatment. Cells were lysed with passive lysis
buffer (Promega) and luciferase activity was assayed using the luciferase assay system
(Promega) according to the manufacturer’s instructions.
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SDS-Page and Western Blotting. Total cell lysate from approximately 105 EC
was resolved using Bis-Tris buffered SDS-PAGE gels ranging from 8-12% depending on
the protein of interest. Gels were soaked in protein transfer buffer (48 mM Tris, 39 mM
glycine, 20% methanol, 0.0375% SDS) and transferred to a PVDF membrane using a
BioRad semi-dry transfer cell. After transfer, PVDF membranes were washed briefly in
TBST (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.1% Tween-20) and then blocked for 2
hours in 5% Bovine Serum Albumin in TBST. After blocking, primary antibodies were
diluted 1:1000 in 5% BSA in TBST and incubated overnight at 4°C. Membranes were
washed and then incubated with horseradish peroxidase (HRP) conjugated secondary
antibody for one hour and HRP signals were detected by chemiluminescence.

Quantitative Real-Time PCR. Total RNA was isolated using Qiagen RNeasy
spin columns. First strand cDNA was synthesized using TaqMan reverse transcription
reagents (Roche). cDNA reactions were diluted 6-fold in deionized water and used as a
qRT-PCR template. Reactions were performed using Sybr Green Master Mix (Applied
Biosystems). Gene induction was calculated relative to untreated controls using the 2-ΔΔCt
method.

Immunoprecipitation. EC were washed once with ice-cold PBS and lysed in
RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 150 mM NaCl, 0.1% SDS, 1 mM
EDTA, 5 mM Na3VO4) supplemented with protease inhibitor cocktail (Roche) and
phosphatase inhibitors (Roche). Lysis was allowed to proceed for 30 minutes at 4°C
under gentle agitation. Lysates were cleared by high-speed centrifugation and primary
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antibodies were added for overnight incubation. Antibody complexes were precipitated
with protein A/G-agarose beads, washed three times with ice cold RIPA, and denatured
with 3x Laemmli buffer for SDS-PAGE.

Quantitative mass spectrometry. After immunoprecipitation with an antiSTAT3 antibody, an 86 kDa band was cut from Coomassie-stained gel, digested with
trypsin, and analyzed by capillary column LC- tandem MS to identify phosphopeptides.
The LC-MS system was a Finnigan LTQ linear ion trap mass spectrometer system. The
HPLC column was a self-packed 9 cm x 75 µm id Phenomenex Jupiter C18 reversedphase capillary chromatography column. The digest was analyzed using the data
dependent multitask capability of the instrument acquiring full scan mass spectra to
determine peptide molecular weights and product ion spectra to determine amino acid
sequence in successive instrument scans. The data were analyzed by using all CID
spectra collected in the experiment to search the NCBI non-redundant database with the
search program Mascot using a human taxonomy filter. All matching spectra were
verified by manual interpretation. The interpretation process was aided by additional
searches using the programs Sequest and Blast as needed.

Phospho-kinase protein array. The Human Phospho-kinase Antibody Array was
purchased from R&D Systems. 500µg of HUVEC protein was incubated with the array
membranes overnight at 4ºC under gentle agitation. Membranes were washed and then
incubated with a phospho-antibody detection cocktail for two hours at room temperature.
Membranes were washed and then incubated with a streptavidin-HRP containing solution
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for 30 minutes at room temperature. After extensive washing, phosphorylation was
detected by chemiluminescence and relative changes were quantified using ImageJ
software.

STAT3 DNA-binding assay. STAT3 DNA binding activity was measured using
the TransAM transcription factor ELISA kit from Active Motif according to the
manufacturer’s instructions. Briefly, stimulus-treated EC were harvested in hypotonic
lysis buffer (25 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2) and lysed at 4°C for
30 minutes to release cytosolic proteins. Cytosolic fractions were collected, EC pellet was
washed once with hypotonic lysis buffer, and nuclear proteins were extracted with highsalt lysis buffer (25 mM HEPES pH 7.5, 420 mM KCl, 1.5 mM MgCl2, .2 mM EDTA,
10% glycerol) to collect the nuclear fraction. Nuclear extract was diluted in DNA
binding buffer according to the manufacturer’s instructions. 10 µg of nuclear extract was
added to each well of a 96-well plate that was coated with oligonucleotides containing
consensus GAS elements (5’-TTCCCGGAA-3’), and incubated at room temperature for
1 hour. Unbound nuclear proteins were washed away, and DNA-bound STAT3 was
detected with an anti-STAT3 antibody, followed by colorimetry using TMB as a
chromogenic substrate.

Immune-complex kinase assay. An AKT kinase assay kit (#9840) was
purchased from Cell Signaling Technology. Briefly, EC were treated with agonists for 10
minutes and lysed with a proprietary lysis buffer containing protease and phosphatase
inhibitors. Insoluble cellular material was removed by centrifugation (16,000xg) and the
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supernatant was used for immunoprecipitation. Total AKT was precipitated with panAKT antibody (Cell Signaling, #4691). A portion of the immunoprecipitate was diluted
400-fold for the in vitro kinase assay. Recombinant GST-tagged GSK3α was used as an
AKT substrate and incubated in the presence of ATP for 30 minutes. Reaction was
stopped with 4x SDS loading buffer and GSK3α was resolved by SDS-PAGE and blotted
with an anti-phospho- GSK3α antibody (#9327).

BrdU proliferation assay. BrdU incorporation was measured using a BrdU
proliferation kit (Cell Signaling Technology #6813) according to the manufacturer’s
instructions. EC were serum-starved overnight and then treated with agonists for 8 hours.
BrdU labeling was performed between 8-12 hours without removing treatment media.

Endothelial wound healing. HUVEC were seeded in 6-well plates in full growth
medium. Cells were washed twice with serum-free MCDB and serum-starved for 2 hours.
Linear wounds were created using a 200 µl pipette tip, cells were washed once with
MCDB, and phase contrast images were taken to capture wound size prior to treatment.
Cells were then stimulated with agonists and allowed to migrate for 16 hours. Wounds
were imaged again and the percent of scratch closure was calculated using ImageJ
software and comparing the wound size of specific fields before and after migration.

Monocyte adhesion assay. HUVEC were serum-starved for two hours and
treated with agonists for 6 hours. U937 monocytes were maintained in RPMI in 10%
FBS. U937 cells were washed once and labeled with 2 µM Calcein-AM (Invitrogen) in
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MCDB for 15 minutes. U937 cells were washed twice before adding 2x10^6 monocytes
to each well of activated EC after removing EC treatment media. Binding was allowed to
proceed for 30 minutes, after which adhered monocytes were counted by fluorescent
microscopy of EC-bound monocytes.

Statistical analyses. Unless otherwise indicated, data are expressed as means +/SEM. Differences between groups were analyzed by analysis of variance (ANOVA).
Bonferroni post-hoc tests were performed to evaluate pairwise differences between
groups. Synergism Ratio (SREGF+TRAP) = ResponseEGF+TRAP / (ResponseEGF +
ResponseTRAP), where the response is the stimulus-inducible value. To calculate the
presence of a synergism, a one-sample t-test was performed by comparing the mean SR
to a hypothetical value of 1.0. Significance is expressed as: *,p<0.05; **,p<0.01;
***,p<0.001.

List of Reagents. A comprehensive list of reagents, kits, antibodies, and primers
used in this study can be found in the appendix in Tables II-VIII.
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2.4

Results
Synergistic induction of multiple IEGs following simultaneous EGFR and

PAR-1 activation.
To investigate the effect of simultaneous EGFR/PAR-1 activation on IEG
induction, we treated EC with EGF, thrombin receptor agonist peptide (TRAP), or both
for one hour (30 minutes for c-Fos) and measured IEG mRNA expression. We calculated
a SR by dividing the response to combined stimulation with EGF plus TRAP by the sum
of individual responses to EGF or TRAP alone. The transcription factors early growth
response 1 and 3 (EGR1, EGR3), and c-Fos were induced with SRs of 2.18, 10.1, and
4.11, respectively (Figure 7). The prostanoid synthase cyclooxygenase-2 (COX-2) was
induced with a SR of 1.52, and interleukin-8 (IL-8) displayed a SR of 2.20 (Figure 7).
Protein levels of EGR1 and MKP-1 were also synergistically increased following dual
EGF plus TRAP treatment with SRs of 1.96 +/- 0.09 and 2.95 +/- 0.84, respectively
(Figure 7, bottom-right).
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Figure 7. Simultaneous EGFR/PAR-1 activation synergistically induces multiple IEGs. EC
were treated with EGF (16 ng/ml), TRAP (100 µM), or both for 30 minutes (c-Fos) or 1 hour
(EGR1, EGR3, COX-2, IL-8). Cells were lysed, total RNA was isolated, and processed for qRTPCR analysis. Data represent the mean and SEM from 3 independent experiments. Synergism
Ratio (SREGF+TRAP) = ResponseEGF+TRAP / (ResponseEGF + ResponseTRAP). Bottom right,
immunoblots of EC lysates treated for one hour with the indicated agonists.
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We selected EGR1 as an endpoint to investigate the molecular mechanism of
EGFR/PAR-1 crosstalk. In the presence of EGF, thrombin or TRAP displayed similar
synergistic induction of EGR1 protein (EGF+thrombin SR = 2.57 +/- 0.82; EGF+TRAP
SR = 2.57 +/- 0.52) (Figure 8). The kinetics of EGR1 expression were similar under all
conditions, peaking at one hour and returning toward basal levels by three hours (Figure
9), suggesting that EGFR/PAR-1 crosstalk controls the magnitude, but not the kinetics, of
IEG expression. EGR1 is occasionally expressed in both a high molecular weight (~75
kDa) and low molecular weight (~57 kDa) form (227). We observe the 75 kDa species in
all experiments, but the 57 kDa form is rarely induced. Pretreatment of EC with
cyclohexamide, an inhibitor of de novo protein synthesis, had no effect on EGR1 mRNA
induction or the EGFR/PAR-1 synergism (Figure 10), demonstrating that EGR1 was
induced as an IEG.

Figure 8. Thrombin and TRAP induce synergistic EGR1 expression in combination with
EGF. Serum-starved EC were treated with EGF (16 ng/ml), TRAP (100 µM), or thrombin
(5U/ml) for 1 hour and EGR1 was detected by immunoblot. Densitometry analysis was
performed using ImageJ densitometry software and represents the quantification of 3 independent
immunoblots.
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Figure 9. Timecourse of EGR1 induction. EC were serum-starved for 2 hours and then treated
with EGF, TRAP or both for up to 3 hours. EGR1 induction was analyzed by immunoblot.

Figure 10. De novo protein synthesis is not required for synergistic EGR1 induction.
EC were serum-starved for 2 hours, and pre-treated with PBS or cyclohexamide (CHX, 1 µg/ml)
for 30 minutes. EC were then treated for 60 minutes with EGF (16 ng/ml), TRAP (100 µM), or
both, and inducible EGR1 mRNA expression was measured by qRT-PCR analysis.
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ERK-independent coincidence detection underlies synergistic EGR1 induction.
Numerous publications have reported that EGR1 induction is mediated by the
MAP kinase ERK1/2 in response to various agonists, including EGF (228, 229). To
determine specific pathways mediating EGR1 induction by EGF plus TRAP, we pretreated EC with the MEK1 inhibitor PD98059 to prevent ERK activation. PD98059
treatment almost completely inhibited EGR1 induction in response to individual
treatment with EGF or TRAP (Figure 11). However, when cells were treated with EGF
and TRAP simultaneously, an ERK-independent portion of EGR1 induction was
triggered with a high degree of synergism (SR = 19.88) (Figure 13). In a signal
transduction network, a SR of this magnitude suggests the presence of a signaling node
that effectively functions as a Boolean AND gate; whereby, a cellular output (EGR1
induction) is elicited only when two stimuli (EGF and TRAP) are simultaneously present.
This result revealed two important facts about the mechanism of EGFR/PAR-1
synergism. First, synergistic EGR1 induction occurs via two distinct signaling pathways
(ERK-dependent and ERK-independent). Second, at some level, the ERK-independent
pathway likely utilizes a mechanism of coincidence detection to induce ERK-independent
EGR1 expression only when EGFR and PAR-1 are simultaneously activated.
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Figure 11. Synergistic EGR1 induction is ERK-independent. EC were pre-treated for 30
minutes with the MEK1 inhibitor PD98059 (10 µM). EC were treated with EGF (16 ng/ml),
TRAP (100 µM), or both for 1 hour and EGR1 was measured by immunoblot. Graph represents
the mean +/- SEM from 4 independent experiments.

The ERK-independent pathway was sensitive to the EGFR kinase inhibitor
AG1478 (Figure 12), which completely inhibited EGF-induced EGR1 and prevented a
synergism during simultaneous EGF plus TRAP treatment (SR = 1.15 +/- 0.23) (Figure
12). This result revealed that in addition to the canonical pathway of ERK activation,
EGFR kinase activity is also required to initiate the alternative, synergistic pathway of
EGR1 induction. Therefore, combinatorial EGFR/PAR-1 signaling must be integrated at
some downstream signaling node that functions as an AND gate to induce EGR1
following coincident receptor activation (Figure 13).
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Figure 12. Synergistic pathway of EGR1 induction requires EGFR kinase activity. EC were
pre-treated for 30 minutes with the EGFR kinase inhibitor AG1478 (1 µM). Treatments and
immunoblots were performed as in (Figure 11). Graph represents the mean +/- SEM from 3
independent experiments.

Figure 13. ERK-independent pathway functions as a cellular coincidence detector.
SRs from individual experiments were averaged to calculate a mean SR and SEM. Data represent
the synergism ratio of EGR1 induction when the indicated agonist (x-axis) was used to stimulate
EC in the presence of EGF.
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STAT3 is required for detection of coincident EGFR/PAR-1 activation.
To identify candidate transcription factors involved in ERK-independent EGR1
induction, we examined the promoter regions of the six gene targets of the EGFR/PAR-1
synergism for common transcription factor binding sites. Using a combination of
literature-based searches and web-based bioinformatics tools, (P-match and TFSEARCH)
we compiled a list of potential transcription factor binding sites for each of the six IEGs
(Figure 14). Several common transcription factors were identified, including ELK-1, the
downstream target of the ERK1/2 signaling pathway that mediates EGR1 induction (230,
231), and CREB, most commonly activated by protein kinase A (PKA). PKA inhibition
did not affect synergistic induction of EGR1 following EGF plus TRAP treatment (Figure
15), so we did not pursue further experiments on CREB signaling. Notably, every
synergistically-induced gene had at least one potential binding site for a STAT
transcription factor. Further examination revealed that these candidate STAT binding
sites were consensus STAT3 binding elements (Gamma-IFN-activated sequences, GAS
elements) (See appendix, Table II). Each of the six IEGs contained a putative STAT3
binding site between ~1.4-1.8 kb upstream to the transcription initiation site (Figure 16),
raising the possibility that STAT3 was a component of the ERK-independent coincidence
detector.
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Figure 14. In silico analysis of DNA elements in the EGR1 promoter. Promoter regions from
synergistically induced IEGs were scanned for candidate transcription factor binding sites (up to
2 kb from the transcription initiation start site). Two freely available, web-based searches were
used: P-match (www.gene-regulation.com/cgi-bin/pub/programs/pmatch/bin/p-match.cgi) and
TFSEARCH (www.cbrc.jp/research/db/TFSEARCH.html), and matches were cross-checked
between programs. Conflicting results were evaluated by literature-based searches, and if a
conflict could not be resolved, the candidate binding site was included in the comparison to
increase the number of possible matches. It is important to note that the main purpose of this
bioinformatic approach was to generate hypotheses. Therefore, the figure does not constitute a
comprehensive list of possible transcription factor sites.
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Figure 15. Protein kinase A activity is not required for synergistic EGR1 induction. Serumstarved EC were pre-treated for 30 minutes with the Protein Kinase A inhibitor KT5720 (1 µM).
Cells were treated with EGF, TRAP, or both for 1 hour and EGR1 was detected by immunoblot.

Figure 16. Candidate STAT3 binding sites are present in all six synergistically induced
genes. Illustration showing the location of candidate STAT3 binding elements within the
promoter regions of six synergistically-induced IEGs.
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siRNA-mediated knockdown of STAT3 completely inhibited the synergistic
induction of EGR1 protein and mRNA (Figure 17) without affecting EGR1 levels
induced by EGF or TRAP alone. STAT3 knockdown significantly reduced the SR of
inducible EGR1 protein (2.86 to 0.89) and mRNA (2.09 to 1.14) (Figure 18), suggesting
a complete loss of function of EGFR/PAR-1 crosstalk. Similarly, the induction of another
synergistically induced IEG, MKP-1, was inhibited when STAT3 protein was depleted by
RNAi (Figure 19). These results provide convincing evidence that STAT3 is a critical
transcription factor mediating the EGFR/PAR-1 synergism, and they implicate STAT3 in
the mechanism of coincidence detection observed in experiments with PD98059 (Figure
11, 13).

Figure 17. STAT3 is required for synergistic induction of EGR1. (Left) EC were transfected
with non-targeting or STAT3-targeting siRNA. 48 hours post-transfection, EC were treated with
EGF, TRAP, or both for 1 hour and EGR1 was measured by immunoblot. (Center) Densitometry
analysis of 4 independent immunoblots. (Right) STAT3 was depleted by RNAi, and EGR1
mRNA was measured by qRT-PCR. Data are averaged from 3 experiments and expressed as fold
induction relative to untreated controls and normalized to levels of GAPDH mRNA.
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Figure 18. Synergism ratio of inducible EGR1 in the presence or absence of STAT3. SRs for
experiments using STAT3 siRNA. Dashed line at y = 1 represents an additive response.

Figure 19. STAT3 is required for MKP-1 induction in response to EGF plus TRAP. EC were
transfected with non-targeting or STAT3-targeting siRNA. 48 hours post-transfection, EC were
treated with EGF (16 ng/mL), TRAP (100 µM), or both for 1 hour and MKP-1 was measured by
immunoblot.
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STAT3 activity is primarily regulated by two post-translational modifications
(232). Phosphorylation of STAT3 at Tyr705 leads to dimerization and permits DNAbinding (123). STAT3 Ser727 phosphorylation, a modification within the COOH-terminal
transactivation domain (TAD), facilitates physical interactions between STAT3 and
histone acetyltransferases (163, 233), and is required for full transcriptional activity of
STAT3 (159). We hypothesized that if STAT3 is the node of integration for detecting
simultaneous EGFR/PAR-1 activation, then there should be some unique regulation of
STAT3 during co-treatment with EGF plus TRAP. EGF treatment per se weakly induced
Tyr705 phosphorylation (Figure 20), and this modification was not significantly affected
by co-treatment with TRAP. Strikingly, STAT3 Ser727 phosphorylation did not occur in
response to either EGF or TRAP alone, but was significantly increased when cells were
simultaneously stimulated with EGF plus TRAP (Figure 20), suggesting that Ser727
phosphorylation is a mediator of coincidence detection following EGFR/PAR-1
activation. To verify the synergistic phosphorylation of Ser727, STAT3 was
immunoprecipitated from EC following agonist exposure, and Ser727 phosphorylation was
measured by quantitative mass spectrometry (Figure 21). Again, neither EGF nor TRAP
induced a significant increase in Ser727 phosphorylation. However, Ser727 phosphorylation
was markedly increased following co-treatment with EGF plus TRAP, suggesting that
STAT3 Ser727 is a point of convergence for pathways of EGFR/PAR-1 crosstalk.
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Figure 20. STAT3 Ser727 phosphorylation is strongly induced by EGF plus TRAP. (Left) EC
were stimulated for 5 minutes with EGF (50 ng/ml), TRAP (100 µM), or both. STAT3
phosphorylations were detected by immunoblotting with antibodies specific for Tyr705 and Ser727
phosphorylation. (Center) Quantification of STAT3 Tyr705 phosphorylation from 4 independent
immunoblots. (Right) Quantification of STAT3 Ser727 phosphorylation.

Figure 21. Quantitative mass spectrometry analysis of STAT3 Ser727 phosphorylation.
HUVEC were treated for 5 minutes with EGF (16, ng/ml), TRAP (100 µM), or both.
Phosphorylation was quantified by comparing the relative abundance of STAT3 Ser727
phosphopeptides to unmodified STAT3 peptides. Data are averaged from 2 independent
experiments.
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Ser727-phosphorylated STAT3 positively regulates synergistic EGR1 induction via a
distal GAS element.
We cloned a ~2kb fragment of the human EGR1 promoter region upstream of a
luciferase reporter to investigate the role of STAT3 Ser727 phosphorylation in synergistic
EGR1 induction (Figure 22, 23). Previous studies of the EGR1 promoter demonstrated
that the ELK-1 and SRF binding sites within the proximal promoter region are critical for
promoter activation in response to various stimuli including thrombin and EGF (231,
234–237). EGR1 promoter activity was synergistically increased in cells transfected with
WT-STAT3 in response to EGF plus TRAP. (Figure 24). A STAT3 S727A mutation
significantly decreased EGF plus TRAP induced EGR1 promoter activity and prevented a
synergism during co-treatment (Figure 24), suggesting that STAT3 Ser727 is critical for
promoter activation during EGFR/PAR-1 crosstalk.

Figure 22. Map of EGR1 promoter. Illustration showing location of transcription factor binding
sites within the human EGR1 promoter. Detailed sequence information is depicted in Figure 23.
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Figure 23. Sequence of cloned EGR1 promoter. The figure displays the full cloned sequence of
human EGR1 promoter used in luciferase reporter assays. A partial list of consensus binding sites
have been highlighted and color-coded. Primers used to clone this DNA fragment from human
genomic DNA are listed in Table VIII.

Figure 24. STAT3 Ser727 is required for synergistic activation of EGR1 promoter. (Left)
HUVEC were co-transfected with EGR1-promoter luciferase reporter and WT-STAT3 or
STAT3-S727A. 24 hours post-transfection, EC were serum-starved for 4 hours prior to
stimulation with EGF, TRAP, or both for 4 hours. Luciferase activity was measured using a
luminometer. (Right) SRs for luciferase reporter experiments using STAT3-WT and STAT3
S727A. Dashed line at y = 1 represents an additive response.
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Mutation of the distal GAS element, but not the proximal GAS element,
significantly inhibited EGF plus TRAP induced promoter activity (Figure 25). Because
MAPK signaling pathways are active in this context, residual promoter activity of the
distal GAS mutant is likely due to EGF-induced activation of serum-response elements
(SREs) within the proximal promoter (234, 238). Next, we measured the DNA-binding
activity of STAT3 in response to EGF plus TRAP treatment using a DNA-binding
ELISA assay. Surprisingly, we found that untreated STAT3 exhibited DNA-binding
activity (Figure 26). Stimulation of EC with EGF or TRAP for 15 minutes did not affect
STAT3 DNA binding, but co-treatment induced a ~2-fold increase in STAT3-specific
DNA binding activity. Together, these results demonstrate that simultaneous activation of
EGFR and PAR-1 causes synergistic activation of the EGR1 promoter via a distal GAS
element in a manner that requires STAT3 Ser727 phosphorylation.

Figure 25. Distal GAS element in EGR1 promoter is required for maximal promoter
activity. EC were transfected with EGR1-promoter luciferase reporter or constructs containing
mutations in the distal GAS element (TTCCCGGAA ! gcgCCGGAA) or proximal GAS
element (TTCCCCGAA ! gcgCCCGAA). 24 hours post-transfection, inducible luciferase
activity was measured as in Figure 24.
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Figure 26. STAT3 DNA-binding activity in HUVEC. DNA-binding activity of STAT3 was
measured using a TransAM ELISA from ActiveMotif. EC were stimulated with indicated
treatments for 15 minutes, and nuclear extracts were incubated at room temperature in a 96-well
microplate coated with oligonucleotides containing consensus GAS-elements. Nuclear extract
was washed away and DNA-bound STAT3 was detected using an anti-STAT3 antibody and
colorimetry using TMB as a chromogenic substrate. Individual extracts were processed in
duplicate wells and data represent the mean and SEM of 2 independent experiments.

Coincident EGFR/PAR-1 signaling prevents EGF-induced AKT activation.
To identify signaling pathways involved in combinatorial regulation of STAT3
Ser727 phosphorylation, we used a phospho-kinase signaling array (R&D Systems) to
examine the relative activation of various cell signaling intermediates following
individual or combined stimulation with EGF and thrombin. The protein array was
composed of nitrocellulose membranes spotted with antibodies for cell signaling
mediators, and phosphorylation was detected by chemiluminescence with anti-phosphotyrosine, threonine, and serine antibodies (Figure 27).
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Figure 27. Thrombin treatment prevents EGF-induced AKT phosphorylation. (Left)
Phospho-kinase array (R&D Systems, Catalog # ARY003) was performed according to the
manufacturer’s instructions. Briefly, EC were treated with EGF, thrombin, or both for 10 minutes.
EC were lysed with a proprietary lysis buffer and lysates were incubated with antibody-spotted
nitrocellulose membranes. Relative phosphorylation was detected with anti-phospho-Tyr, Thr,
and Ser secondary antibodies. (Right) Heatmap of data from protein array was created after
quantification using ImageJ software. Raw data is available in Table III in the appendix. Heatmap
was generated using R-project statistical graphing software, and expressed as fold induction
relative to untreated controls for each antibody.
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The results of the phosphokinase array experiment are summarized in the heatmap
(Figure 27), and detailed in Table III in the appendix. As expected, EGF treatment
induced the phosphorylation of numerous signaling molecules including ERK1/2,
MSK1/2, eNOS, AKT, and GSK-3α/β. TRAP treatment also induced phosphorylations of
known, thrombin-regulated proteins (c-Src, CREB). The most dramatic feature of the cotreatment condition was a striking inhibition of AKT phosphorylation at Ser473 relative to
cells treated with EGF alone (Figure 27, box, bottom; heatmap, top row). Further analysis
revealed that phosphorylation of known AKT substrates, including eNOS and GSK-3α/β
(Figure 27, box, top), was also reduced during simultaneous EGF plus TRAP treatment
(Appendix, Table VIII). This observation raised the possibility that EGF plus TRAP
treatment modulates AKT-mediated signaling pathways by inhibiting AKT activity.
Results of the protein array were confirmed by immunoblotting to detect phosphorylation
of AKT. EGF treatment strongly induced phosphorylation of AKT Ser473, and this
increase was significantly inhibited by simultaneous EGF plus TRAP treatment (Figure
28). The inhibition appeared to be specific to AKT signaling, as ERK1/2 phosphorylation
was not reduced during EGF plus TRAP treatment (Figure 27, 28).

65

Figure 28. PAR-1 activation prevents EGF-induced AKT phosphorylation. EC were treated
as in Figure 27 with TRAP substituted for thrombin, and levels of phosphorylated ERK and AKT
were detected by immunoblot. (Right) Quantification of 5 immunoblots of experiments
performed as in the left panel.

EGFR does not have direct binding sites for the SH2 domain of PI3K, but
activates the PI3K-AKT signaling axis via adaptors proteins such as GAB1 (239–241).
Phosphorylation of EGFR at Y1068 and Y1086 are the predominant GAB1-binding sites
for activation of PI3K (241). We investigated whether PAR-1 activation could modulate
EGF-induced phosphorylation at these sites to prevent AKT phosphorylation in response
to EGF. Co-treatment with EGF and TRAP did not significantly affect total tyrosine
phosphorylation of EGFR, pY1068, or pY1086 (Figure 29), suggesting that PAR-1
activation inhibits EGF-induced AKT phosphorylation through a downstream signaling
mechanism.
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Figure 29. Analysis of EGFR phosphorylation in response to EGF plus TRAP. EC were
treated with EGF (50 ng/ml), TRAP (100 µM), or both for 5 minutes. Cells were lysed in ice-cold
RIPA buffer and EGFR was immunoprecipitated with anti-EGFR antibody overnight.
Immunoprecipitate was resolved by SDS-PAGE, and total or site-specific tyrosine
phosphorylation was analyzed by immunoblot.

Next, we systematically inhibited PAR-1-coupled Gα proteins to identify the Gα
member responsible for inhibition of EGF-induced AKT activation. Individual
knockdown of Gαq, Gα12, and Gα13, or inhibition of Gαi by pertussis toxin did not
significantly affect the ability of PAR-1 to inhibit AKT activation in response to EGF
(Figure 30). However, dual knockdown of Gα12 and Gα13 caused an increase in AKT
phosphorylation in response to EGF plus TRAP treatment (Figure 31). Together, these
data suggest that PAR-1 activation inhibits EGF-induced AKT Ser473 phosphorylation in
a Gα12/13-dependent manner without any detectable changes in EGFR phosphorylation.
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Figure 30. Role of Gα subunits in PAR-1-mediated inhibition of AKT phosphorylation.
(Top-left) Confluent EC were pre-treated with pertussis toxin (250 ng/ml) or PBS for 30 minutes,
after which they were treated with EGF, TRAP, or both for 5 minutes. AKT Ser473
phosphorylation was analyzed by immunoblot. (Top-right) EC were transfected with nontargeting or Gαq-targeting siRNA. 48 hours post-transfection, EC were treated with EGF (16
ng/mL), TRAP (100 µM), or both for 5 minutes and AKT Ser473 phosphorylation was analyzed
by immunoblot. (Bottom-left) EC transfected with Gα12 siRNA, (Bottom-right) EC transfected
with Gα13 siRNA, and treated as in the top panels.

Figure 31. Gα12/13 are required for PAR-1-dependent inhibition of AKT phosphorylation.
EC were transfected with non-targeting or Gα12/13-targeting siRNA. 48 hours post-transfection,
EC were treated with EGF (16 ng/mL), TRAP (100 µM), or both for 5 minutes and AKT Ser473
phosphorylation was analyzed by immunoblot.
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Inhibition of AKT is required for STAT3 Ser727 phosphorylation and enhanced
EGR1 expression.
To test whether the inhibition of AKT signaling was involved in enhancing EGR1
expression, we did a side-by-side comparison of EGF plus TRAP-treated cells and cells
treated with EGF plus the PI3K inhibitor, LY294002. EGF treatment strongly induced
AKT Ser473 phosphorylation at 5 minutes, and both EGF plus TRAP and EGF plus
LY294002-treated cells showed little to no AKT phosphorylation relative to EGF-treated
cells (Figure 32). In both cases, the inhibition of AKT phosphorylation at 5 minutes
preceded an increase in EGR1 induction at 60 minutes (Figure 32) relative to cells treated
with EGF alone. EGF plus TRAP and EGF plus LY294002 induced EGR1 to similar
levels relative to EGF-treated cells (Figure 32), suggesting that modulation of EGFinduced AKT signaling by PAR-1 is a critical step in STAT3-dependent EGR1 induction.
Further, EGF-induced EGR1 promoter activity was significantly increased in EC
expressing a DN-AKT construct relative to a WT-AKT expressing cells (Figure 33).
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Figure 32. Inhibition of PI3K increases EGF-induced EGR1 expression. EGF, TRAP, and
EGF plus TRAP-induced AKT phosphorylation and EGR1 induction were compared to EGF
signaling in the presence of a PI3K inhibitor. EC were serum-starved for 90 minutes and then
incubated with DMSO or LY294002 for an additional 15 minutes before treatment with indicated
agonists. AKT phosphorylation and EGR1 induction were determined by immunoblot. (Right)
Quantification of 2 independent experiments performed as in the left panels.

Figure 33. AKT activity suppresses EGR1 promoter activity in response to EGF. HUVEC
were co-transfected with EGR1-promoter luciferase reporter and WT-AKT or DN-AKT. 24 hours
post-transfection, EC were serum-starved for 4 hours prior to stimulation with EGF, TRAP, or
both for 4 hours. Luciferase activity was measured using a luminometer and data represent 4
independent experiments.
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To investigate whether the inhibition of AKT kinase activity was required for
STAT3 Ser727 phosphorylation, EC were incubated for 15 minutes with either DMSO or
the PI3K inhibitor LY294002, after which they were treated with agonists for five
minutes, and STAT3 was immunoprecipitated to assess Ser727 phosphorylation by
immunoblot. Similar to previous results (Figure 20, 21), individual EGF treatment did not
induce Ser727 phosphorylation. However, in the presence of a PI3K inhibitor, Ser727
phosphorylation was EGF-inducible (Figure 34), demonstrating that inhibition of AKT
activity is a prerequisite for EGF-induced Ser727 phosphorylation. Further, this result
demonstrates that the TRAP-mediated inhibition of EGF-activated AKT is likely the
mechanism by which STAT3 Ser727 phosphorylation occurs during coincident
EGFR/PAR-1 activation.

Figure 34. STAT3 Ser727 phosphorylation is EGF-inducible during PI3K inhibition. HUVEC
were transfected with recombinant V5-tagged STAT3. Cells were pre-treated with DMSO or
LY294002 for 15 minutes before treatment with EGF for 5 minutes. Recombinant STAT3 was
immunoprecipitated using anti-V5 antibody and STAT3 Ser727 phosphorylation was analyzed by
immunoblot.

71

We next examined the effect of combinatorial EGFR/PAR-1 signaling on AKT
kinase activity. Two phosphorylation sites are involved in AKT activation, Thr308 and
Ser473 (242), and phosphorylation at both sites was reduced by EGF plus TRAP cotreatment (Figure 35).

Although the mechanism by which this inhibition occurs is

unclear, this result suggests that it is upstream to AKT, rather than a regulation of AKT
itself. Next, AKT activity was measured via an immune-complex kinase assay (Figure
35). AKT that was immunoprecipitated from EGF-treated cells strongly phosphorylated a
GST-GSK-3α fusion protein, while TRAP-treated AKT showed little to no activity
(Figure 35). EGF plus TRAP treatment significantly reduced the ability of AKT to
phosphorylate the GST-GSK-3α fusion protein compared to EGF-treated AKT,
indicating a significant reduction in AKT kinase activity during co-stimulation with EGF
plus TRAP (Figure 35). Additionally, EGF-induced GSK-3α/β phosphorylation was
completely inhibited by pre-treatment with a PI3K inhibitor (Figure 36), indicating that
EGF-induced AKT activity is likely the primary mediator of EGF-induced GSK-3α/β
phosphorylation in EC.
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Figure 35. EGF plus TRAP treatment decreases AKT kinase activity. Serum-starved EC were
treated with agonists for 5 minutes. Cells were lysed, and total AKT was immunoprecipitated
using a pan-AKT antibody (Cell Signaling, #4691). A portion of the lysate (~10%) was diluted
400-fold in kinase assay buffer and incubated with recombinant GST-GSK3-α fusion protein. The
majority of lysate was used for immunoblot analysis to determine levels of AKT phosphorylation.
Densitometry values (right) represent the mean +/- SEM of 3 immune-complex kinase assays.

Figure 36. GSK-3α/β Ser21/Ser9 phosphorylation is downstream of PI3K. EC were pretreated with DMSO or LY294002 (10µM) for 15 minutes before treatment with EGF (16 ng/ml)
for 5 minutes. GSK-3α/β phosphorylation was analyzed by immunoblot.
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AKT-mediated phosphorylation of GSK-3α at Ser21 and GSK-3β at Ser9 leads to
autoinhibition and reduced activity toward downstream substrates (243–245). We
hypothesized that a reduction in the inhibitory phosphorylation of GSK-3α/β during EGF
plus TRAP treatment could allow GSK-3α/β to participate in STAT3 Ser727
phosphorylation. The compound CHIR99021, a potent and highly specific inhibitor of
GSK-3α/β (246), reduced Ser727 phosphorylation in response to EGF plus TRAP (Figure
37, 38, 39), but roscovitine, a cyclin-dependent kinase inhibitor, and rapamycin, an
inhibitor of mTOR signaling, had no effect (Figure 38, 39). These results demonstrate
that GSK-3α/β kinase activity is required for EGF plus TRAP induced Ser727
phosporylation, thus placing GSK-3α/β in the STAT3-dependent, non-canonical pathway
of EGR1 induction. Simultaneous knockdown of GSK-3α/β by RNAi significantly
reduced EGF plus TRAP-induced EGR1 expression, while individual knockdown of
GSK-3α or GSK-3β did not significantly affect EGR1 induction (Figure 40).

Figure 37. GSK-3α/β kinase activity positively regulates STAT3 Ser727 phosphorylation. EC
were pre-treated for 30 minutes with the GSK-3α/β inhibitor CHIR99021 (1 µM) and then
stimulated for 5 minutes with EGF, TRAP, or both. STAT3 phosphorylations were detected by
immunoblot.
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Next, we investigated whether GSK-3α/β activity was required for ERKindependent EGR1 expression. The MEK1 inhibitor PD98059 inhibited ~50% of EGF
plus TRAP-induced EGR1 and CHIR99021 inhibited EGR1 induction to an
approximately equal extent (Figure 41). Simultaneous inhibition of MEK1 and GSK-3α/β
completely inhibited EGR1 induction by EGF plus TRAP. Similar results were seen for
the IEG MKP-1, as inhibition of both GSK-3α/β and ERK1/2 was required to completely
inhibit MKP-1 protein induction in response to EGF plus TRAP (Figure 41). This result
shows that, like STAT3, GSK-3α/β function in an ERK-independent pathway that is
independently capable of inducing EGR1 expression in response to simultaneous EGF
plus TRAP treatment. Further, given that GSK-3α/β is required for increased STAT3
Ser727 phosphorylation during EGF plus TRAP treatment (Figure 37, 38, 39), it is
reasonable to conclude that altered GSK-3α/β activity, due to a reduction in AKTmediated inhibitory phosphorylation (Figure 28, 35), is a critical mediator of
EGFR/PAR-1 crosstalk and STAT3-dependent gene expression.
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Figure 38. Effects of Serine/Threonine kinase inhibitors on STAT3 Ser727 phosphorylation.
EC were pre-treated for 30 minutes with the GSK-3α/β inhibitor CHIR99021 (10 µM),
roscovitine (20 µM), or rapamycin (10 nM), and then stimulated for 5 minutes with EGF and
TRAP. STAT3 phosphorylations were detected by immunoblot. Graph represents the mean +/SEM from 3 independent experiments.

Figure 39. Effects of serine/threonine kinase inhibitors on STAT3 Ser727 phosphorylation
measured by quantitative mass spectrometry. EC were pre-treated with the serine-threonine
kinase inhibitors CHIR99021 (1 µM), roscovitine (20 µM), and rapamycin (10 nM). STAT3 was
immunoprecipitated from EGF or EGF plus TRAP treated ECs and immunoprecipitates were
resolved by SDS-PAGE. Gels were stained with coomassie blue solution, an ~86 kDa band was
cut from the gel and Ser727 phosphorylation was analyzed by quantitative mass spectrometry.
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Figure 40. GSK-3α and GSK-3β mediate EGR1 induction in response to EGF plus TRAP.
EC were transfected with control siRNA or siRNA targeting GSK-3α, GSK-3β, or both. 48 hours
post-transfection, cells were treated with EGF, TRAP, or EGF plus TRAP for 60 minutes, and
EGR1 induction was measured by immunoblot. Data represent the mean +/- SEM of 3
independent experiments.

Figure 41. GSK-3α/β-dependent EGR1 induction is ERK-independent. EC were pre-treated
for 30 minutes with the GSK-3α/β inhibitor CHIR99021 (10 µM), PD98059 (10 µM), or both and
then stimulated for 60 minutes with EGF and TRAP. EGR1 and MKP-1 were detected by
immunoblot.
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Coincident EGFR/PAR-1 signaling enhances EC migration in a STAT3-dependent
manner.
EGFR and STAT3 are well-known regulators of cell growth and proliferation. To
investigate how the EGFR/PAR-1 crosstalk affects EC proliferation, serum-starved EC
were stimulated with EGF, TRAP, or both for 8 hours, and BrdU incorporation was
measured between 8-12 hours after agonist exposure (Figure 42). EGF treatment
increased BrdU incorporation to approximately 2.5 fold compared to non-stimulated
cells. TRAP treatment had little to no effect on BrdU incorporation. Interestingly,
simultaneous stimulation of EC with EGF and TRAP caused a ~50% reduction in BrdU
incorporation relative to EGF treatment alone. siRNA-mediated knockdown of STAT3
further reduced EGF plus TRAP-induced BrdU incorporation, suggesting that STAT3 is
critical for EGF-induced DNA synthesis in EC during simultaneous EGFR/PAR-1
activation (Figure 42).
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Figure 42. STAT3 positively regulates EC proliferation. EC were serum-starved for 16 hours
and then treated with agonists in serum-free medium for 8 hours. BrdU was added to wells for 4
hours and cells were fixed in a DNA-denaturing proprietary lysis buffer. BrdU incorporation was
detected by an anti-BrdU antibody and colorimetry using HRP-conjugated secondary antibody
and 3,3’,5,5’-tetramethylbenzadine as a chromogenic substrate. Data represent the mean +/- SEM
for 4 independent experiments.

We previously reported that thrombin induces the expression of leukocyte
adhesion molecules on EC and increases monocyte-EC interactions in vitro (67, 68, 83).
To investigate the effect that combinatorial signaling has on thrombin-induced leukocyteEC interactions, we performed an in vitro monocyte adhesion assay on EGF, thrombin, or
EGF plus thrombin-stimulated EC. We observed very few monocyte-EC interactions
under both untreated and EGF-treated conditions (Figure 43). Thrombin induced a
significant increase in monocyte adhesion to the EC monolayer (Figure 43), and this
effect was almost completely inhibited when EC were simultaneously exposed to both
EGF and thrombin (Figure 43), suggesting that coincident EGFR signaling can at least
partially inhibit thrombin-induced inflammatory signaling. These results provide
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evidence that the known phenotypic responses of EGF-induced proliferation and
thrombin-induced inflammation are both suppressed during combinatorial EGFR/PAR-1
signaling.

Figure 43. EGFR signaling suppresses thrombin-induced leukocyte-EC interactions. An EC
monlayer was treated with indicated agonists for 6 hours, after which agonists were washed away
with serum-free media. Calcein-AM-stained U937 monocytes were added to the stimulated EC
and allowed to adhere for 30 minutes. Non-adhered monocytes were washed away and adhered
monocytes were imaged and quantified per field with ImageJ software. Data represent the mean
+/- SEM from 3 independent experiments.

Previous work from our laboratory demonstrated that simultaneous stimulation of
EC with EGF and TRAP caused a significant increase in EC transwell migration in vitro
(84). We observed a similar synergistic increase in migration when an EC monolayer was
mechanically wounded and then treated with EGF, TRAP, or both for 16 hours (Figure
44). To investigate a potential role for STAT3 in mediating enhanced EC migration, we
depleted STAT3 by RNAi and performed in vitro wound healing assays and measured
the degree of scratch closure. Scratch closure was enhanced in cells stimulated with both
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EGF and TRAP compared to either EGF or TRAP alone (Figure 44). siRNA-mediated
knockdown of STAT3 slightly reduced EGF-induced wound-healing, and completely
inhibited enhanced wound-healing by EGF plus TRAP treatment (Figure 44). These
results suggest that the combinatorial activation of STAT3 causes increased EC
migration, and this increase coincides with a suppression of proliferation and
inflammation elicited by either EGF or thrombin treatments per se.

Figure 44. Combinatorial EGFR/PAR-1 signaling increases EC migration in a STAT3dependent manner. (Left), An EC monolayer was mechanically wounded with a P200 pipette tip
and dislodged cells were washed away with serum-free media. EC were treated with indicated
agonists, and cells were imaged immediately after scratching, and 16 hours post-treatment.
(Middle), EC wound healing assay was performed. EC were transfected with control or STAT3
siRNA 40 hours prior to the experiment. Dashed white lines indicate the boundaries of the
wounds before agonist treatment. (Right), SRs from EC wound healing experiments. Dashed line
at y = 1.0 represents an additive response. One-sample t-test was used to assess the presence of a
significant synergism compared to y=1 (P<.05), and a student’s t-test was used to compare
differences between two groups (P=.053).
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2.5

Discussion
There have been considerable discrepancies regarding EGFR expression in EC

(226). Several studies indicated that EGFR was expressed on human microvascular EC
(MVEC) and that MVEC were responsive to EGF (137, 247), while other reports failed
to detect EGFR expression on both MVEC (136) and HUVEC (136–138). Reports from
our laboratory and others (84, 141, 248, 249) demonstrate that MVEC and HUVEC do
indeed express significant levels of EGFR and are responsive to EGF. Hirata et al. used a
mouse corneal micropocket assay to show that EGF is as potent as VEGF in inducing
angiogenesis in vivo (140). It has also recently been suggested that VEGF-induced EC
migration may be mediated via EGFR transactivation (142). Moreover, although the
expression of EGFR on EC has been debated, it is clear that tumor-associated EC express
EGFR and are responsive to EGF (247, 250). It is important to address the deficiencies in
our knowledge of endothelial EGFR signaling so that we may better understand its role in
endothelial physiology, thereby providing a basis for determining the relative
contribution of endothelial EGFR signaling to disease states like atherosclerosis and
cancer.

It is well-established that PAR-1 and other GPCRs can transactivate RTKs via
inside-out growth-factor signaling in a variety of cell-types (100, 129, 223, 251). Through
this process, GPCRs can induce proliferative, migratory, or invasive phenotypes in an
RTK-dependent manner (128–130). Our results demonstrate that GPCR-mediated
transactivation of RTKs may not be identical to RTK activation per se. Inside-out
autocrine signaling may coincide with intracellular modulation of RTK-dependent
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signaling pathways by GPCR-mediated pathways. While GPCR activation leads to EGFR
transactivation in many contexts, our results raise the possibility that the specific
combinations of signaling pathways propagated from EGFR are determined by coincident
GPCR activation. Therefore, the temporal relationship between GPCR and RTK
activation may have an important effect on EGF-induced phenotypic changes such as
migration and proliferation.

We have shown that STAT3 is required for a non-canonical, ERK-independent
pathway of IEG induction that is triggered by coincident EGFR/PAR-1 activation. EGF
induces the classical STAT3 phosphorylation at Tyr705 (Figure 20), but also initiates an
inhibitory signal through the PI3K-AKT signaling axis that phosphorylates GSK-3α/β,
prevents STAT3 Ser727 phosphorylation, and inhibits STAT3-dependent EGR1 induction.
PAR-1 signaling resolves the conflicting, EGF-activated pathways by preventing AKT
activation, thus permitting GSK-3α/β-dependent STAT3 Ser727 phosphorylation and
ERK-independent EGR1 induction (Figure 45). Similar to our results, others have shown
that coincidence detection in a network-based setting can occur by the introduction of an
activating signal while simultaneously suppressing an inhibitory signal (216).
Collectively, our results describe a novel mechanism by which EGFR and PAR-1
cooperate to form a network-based coincidence detector that regulates STAT3-dependent
gene expression.
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Figure 45. STAT3-mediated coincidence detection regulates a non-canonical pathway of
IEG induction. Either EGF or TRAP is sufficient to induce EGR1 expression via the canonical
ERK1/2 pathway. EGF induces the activating STAT3 phosphorylation at Tyr705, but prevents
STAT3 Ser727 phosphorylation by strongly activating AKT. Activated AKT phosphorylates and
inhibits GSK-3α/β. Coincident PAR-1 signaling inhibits EGF-induced AKT activation, thereby
reducing AKT-mediated phosphorylation and inhibition of GSK-3α/β, and permitting GSK-3α/βdependent STAT3 Ser727 phosphorylation. Simultaneous EGFR and PAR-1 activation causes
increased phosphorylation of both STAT3 Tyr705 and Ser727 and triggers STAT3-dependent IEG
induction.

The EGFR/PAR-1 signaling interaction regulates the magnitude of IEG induction
without any detectable change in the kinetics of expression. We show that maximal
EGR1 induction can be separated into discrete portions, with ERK1/2 and STAT3
mediating independent pathways. It has been shown that alterations in IEG expression,
both in magnitude and duration, can profoundly impact cellular physiology (224, 225,
252). In particular, one recent study showed that the magnitude of EGR1 induction is
critical for digitizing inconsistent or weak growth-factor signals into all-or-nothing
phenotypic outputs (224). As Zwang et al. showed, the degree of EGR1 induction may be
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a critical determinant of cell-cycle progression, where EGR1 expression must exceed a
certain threshold in order for cells to pass a restriction point and initiate DNA synthesis.

GSK-3α/β are multifunctional serine/threonine kinases that are constitutively
active under basal conditions, and undergo rapid inhibition via serine phosphorylation
following growth-factor stimulation (245, 253). Our data demonstrate that GSK-3α/β
activity is critical for a higher-order function of crosstalk by regulating the central node
of coincidence detection between EGFR and PAR-1. Several studies have demonstrated
that GSK-3α/β is critical for crosstalk during cytokine signaling (254–256). Beurel and
Jope showed that inhibitors of GSK-3β signaling reduced STAT3 Tyr705 phosphorylation
in response to interferon-γ and LPS in cell culture and in mouse brain tissue (254, 257).
Interestingly, their signaling studies in Raw 264.7 macrophages showed that STAT3
Ser727 phosphorylation is unaffected by GSK-3α/β inhibition, in contrast to our results,
and indicative of differential regulation of STAT3 by GSK-3α/β depending on the
signaling context. To our knowledge, our results are the first example of GSK-3α/β
mediating growth-factor activation of STAT3, and may represent a novel opportunity for
therapeutic inhibition of STAT3 downstream of oncogenic RTKs.

It is particularly interesting to note that although the observed regulation of
STAT3 Ser727 phosphorylation resembles a strong synergism (Figure 20, 21, 37), STAT3mediated EGR1 expression appears to be almost perfectly gated by combinatorial
EGFR/PAR-1 signaling (Figure 11, 17, 41). In other words, there appears to be a low
level of noise at the signaling node (STAT3) that is not reflected in the cellular output
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(STAT3-dependent EGR1 induction). The exact mechanism by which this noise is
filtered remains unclear. However, it is intriguing to consider the possibility that other
transcription factors may also be required for the STAT3-dependent EGR1 expression. In
our comparison of promoter elements of synergistically induced genes (Figure 14), we
identified several transcription factors that may be common to these genes, including
NFκB family members and CREB. Le Goff et al. reported that CREB1-dependent
expression of the ABCA1 gene required a nearby STAT element (258), suggesting that
cooperation between STATs and CREB may facilitate enhanced gene expression. Our
results clearly show that STAT3 is required for EGR1 induction, but they do not rule out
the possibility that other factors are required to act in concert with STAT3 signaling to
induce EGR1.

We speculate that EC may utilize multiple synergistically activated

transcription factors, working in parallel but required in combination, to filter noise at
signaling nodes and increase the stringency with which STAT3-dependent EGR1
induction is gated by combinatorial signaling.
We have shown that STAT3 essentially functions as a cellular coincidence
detector, triggering EGR1 induction only when EGFR and PAR-1 are simultaneously
activated. Coincidence detection, in this context, reflects an extreme synergism where the
response to multiple agonists is far greater than responses to individual agonists. A largescale analysis of crosstalk in Raw 264.7 macrophages found that although non-additive
events (positive or negative) are relatively common, the prevalence of marked
superadditive responses to pair-wise combinations of agonists is rare (215). In fact, less
than 1.5% of all ligand-pairs in the study demonstrated a significant superadditive
response, and the authors noted that although many ligands fail to induce cytokine
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production by themselves, many ligands display at least one non-additive interaction
when analyzed in combination with another input (215). Thrombin is capable of
activating a variety of intracellular signaling pathways via activation of PAR-1. However,
in many cases, thrombin’s regulation of signaling pathways (e.g. ERK) and cellular
outcomes (e.g. gene expression, migration, angiogenesis) appears to be much weaker
than more potent agonists like EGF and VEGF (84, 106). Our results show for the first
time that perhaps one of the strongest responses elicited by PAR-1 signaling is a
modulation of EGF-induced PI3K-AKT signaling and a triggering of STAT3-dependent
gene expression. We therefore propose that in a combinatorial signaling environment,
where growth-factors likely predominate as the most potent determinants of phenotypic
outcomes, GPCRs like PAR-1 may act as modulators of growth-factor induced signaling
by determining the specificity of RTK-dependent responses.
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3.1

Abstract
Aberrant activation of the ubiquitous transcription factor STAT3 is a major driver

of solid tumor progression and pathological angiogenesis. STAT3 activity is regulated by
numerous posttranslational modifications (PTMs), including Tyr705 phosphorylation,
which is widely used as an indicator of canonical STAT3 function. Herein, we report a
noncanonical mechanism of STAT3 activation that occurs independent of Tyr705
phosphorylation. Using quantitative liquid chromatography-tandem mass spectrometry,
we have discovered and characterized a novel STAT3 phosphoform that is
simultaneously phosphorylated at Thr714 and Ser727 by GSK-3α/β. Both Thr714 and Ser727
are required for STAT3-dependent gene induction in response to simultaneous activation
of EGF receptor (EGFR) and protease-activated receptor-1 (PAR-1) in endothelial cells.
In this combinatorial signaling context, preventing formation of doubly phosphorylated
STAT3, by depleting GSK-3α/β, is sufficient to disrupt signal integration and inhibit
STAT3-dependent gene expression. Levels of doubly phosphorylated STAT3, but not
Tyr705-phosphorylated STAT3, are remarkably elevated in clear cell renal cell carcinoma
relative to adjacent normal tissue, suggesting that the GSK-3α/β-STAT3 pathway is
active in this disease. Collectively, our results describe a functionally distinct,
noncanonical STAT3 phosphoform that positively regulates target gene expression in a
combinatorial signaling context, and identify GSK-3α/β-STAT3 signaling as a potential
therapeutic target in renal cell carcinoma.
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3.2

Introduction
The signal transducer and activators of transcription (STATs) are a family of

seven transcription factors that regulate numerous physiological and pathophysiological
processes including immunity, angiogenesis, cellular survival, metastasis, and
oncogenesis (143, 182). STAT3 is aberrantly activated in a vast majority of human
cancers and is a downstream target of several oncogenic tyrosine kinases including EGF
receptor (EGFR), JAKs, and Src family kinases (SFKs) (122, 259, 260). Consequently,
much research has focused on understanding the role of STAT3 in malignancies, and
studies are ongoing to determine the efficacy of STAT3 inhibition to treat human cancers
(126, 261). It is therefore critical to identify and characterize novel mechanisms of
STAT3 activation in order to elucidate unexplored opportunities to inhibit its function.

A wide range of stimuli including growth factors, oncogenic kinases, and
cytokines can activate STAT3 (262). These stimuli modulate STAT3 function by
regulating a diverse set of PTMs including tyrosine and serine phosphorylation, lysine
acetylation, and lysine and arginine methylation (123, 159, 160, 164–168). Activation of
receptor and non-receptor tyrosine kinases stimulates STAT3 Tyr705 phosphorylation to
induce dimerization and increase STAT3 DNA binding activity (123, 157, 262, 263).
Phosphorylation of Ser727 is mediated by various serine kinases (e.g. MAPKs, CDKs,
PKCs), and this modification increases STAT3 transcriptional activity by facilitating
protein-protein interactions with transcriptional coactivators (159, 163, 262, 264–266).
Acetylation of several lysine residues, most notably Lys685, has also been reported to
regulate STAT3 dimer formation and transcriptional activity (166–169). STAT3 is
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methylated at Lys140 in response to IL-6, and this modification can inhibit or enhance
STAT3-dependent transcription in a gene-specific manner (164). STAT3 has also been
reported to be methylated at Arg31 by PRMT2 to negatively regulate leptin signaling
(165).

The abundance and diversity of STAT3 PTMs suggest that numerous distinctly
modified STAT3 forms (mod-forms) may be simultaneously present in a given cellular
context. Indeed, there potentially exist 2n STAT3 mod-forms, where n is the number of
modified STAT3 sites. As n increases, or as the number of possible PTMs at a single site
increases (e.g. acetylation or methylation of lysine) there is a corresponding exponential
increase in the potential proteomic complexity of STAT3 mod-forms. This mechanism of
proteomic expansion has been suggested to increase the functional repertoire of cellular
proteins, and is likely to confer signal integration potential to STAT3 (267).

We previously reported that STAT3 is a critical signal integrator downstream of
coincident EGFR and protease-activated receptor-1 (PAR-1) signaling in vascular
endothelial cells (EC) (268). In this context, GSK-3α/β-dependent phosphorylation of
STAT3 Ser727 is required to trigger inducible expression of the transcription factor early
growth response 1 (EGR1). Importantly, STAT3-dependent gene expression is triggered
only when EGFR and PAR-1 are simultaneously activated, suggesting that the temporal
information of coincident EGFR/PAR-1 activation is transduced via GSK-3α/β-STAT3
signaling. GSK-3α/β are multifunctional serine/threonine kinases that regulate substrates
with multiple phosphorylation sites in a manner that often requires a “priming”
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phosphorylation (269). Recently, proteome-wide analyses have identified STAT3 Thr714
as a novel phosphorylation site (170–172), but the regulation and function of this
modification have not been investigated.

In this report, we provide evidence that GSK-3α/β directly phosphorylate STAT3
to generate a STAT3 phosphoform that is simultaneously modified at Thr714 and Ser727.
Both Thr714 and Ser727 phosphorylation are required for stimulus-dependent Mcl1
induction in a combinatorial signaling context, suggesting that the doubly modified
phosphoform is the mediator of signal integration and gene induction during
simultaneous EGFR/PAR-1 activation. Levels of doubly phosphorylated STAT3 are
significantly elevated in renal tumors relative to matched normal tissue, suggesting that
the GSK-3α/β-STAT3 signaling axis may be active in this disease. In summary, we
provide a seminal example of temporal information encoding via multisite STAT3
phosphorylation in the context of combinatorial signaling.

3.3

Materials And Methods
Cell-Culture, Transfections, and Treatments. Human EC were isolated by

trypsinization of umbilical veins as previously described (67). EC were plated on
fibronectin coated cell-culture dishes and maintained in MCDB/F12 media containing
15% FBS, .009% heparin, and .015% endothelial cell growth supplement. All
experiments were carried out using cells between the third and fifth passage. EC were
transfected using Targefect reagents (Targeting Systems) according to the manufacturer’s
protocol. Unless otherwise indicated, EC were serum-starved for 2 hours prior to
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treatment with EGF (16 ng/ml), TRAP (100 µM), or thrombin (5U/ml). siRNA targeting
STAT3 (s743), GSK-3α (s6237), and GSK-3β (s6241) were purchased from Life
Technologies. STAT3 3’UTR-targeting siRNA was purchased from Dharmacon (#D003544-19-0005)

SDS-Page and Western Blotting. Total cell lysate from approximately 105 EC
was resolved using Bis-Tris buffered SDS-PAGE gels ranging from 8-12% depending on
the protein of interest. Gels were soaked in protein transfer buffer (48 mM Tris, 39 mM
glycine, 20% methanol, 0.0375% SDS) and transferred to a PVDF membrane using a
BioRad semi-dry transfer cell. After transfer, PVDF membranes were washed briefly in
TBST (150 mM NaCl, 50 mM Tris-HCl, pH7.5, 0.1% Tween-20) and then blocked for 2
hours in protein free TBST blocking buffer (Pierce). After blocking, primary antibodies
were diluted 1:1000 in blocking buffer and incubated overnight at 4°C. Membranes were
washed and then incubated with horseradish peroxidase (HRP) conjugated secondary
antibody for one hour and HRP signals were detected by chemiluminescence. Antibodies
for the following targets were purchased from Cell Signaling Technology (catalog
numbers in parentheses): STAT3 (#9139), STAT3 (#4904), pTyr705 STAT3 (# 9131),
pTyr705 STAT3 (# 9138), pTyr705 STAT3 (# 9145), PMpSP Motif (#2325), pThr-Pro
Motif (#9391), GSK-3α/β (#5676), GAPDH (#5174), Mcl1 (# 5453). Anti-α-Tubulin
(#T5168) antibody was purchased from Sigma Aldrich. Anti-pSer727 STAT3 antibody
(sc-136193)was purchased from Santa Cruz Biotechnology.
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Immunoprecipitation. EC were washed once with ice-cold PBS and lysed in
RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 150 mM NaCl, 0.1% SDS, 1 mM
EDTA, 5 mM Na3VO4) supplemented with protease inhibitor cocktail (Roche) and
phosphatase inhibitors (Roche). Lysis was allowed to proceed for 30 minutes at 4°C
under gentle agitation. Lysates were cleared by high-speed centrifugation and primary
antibodies were added for overnight incubation. Antibody complexes were precipitated
with protein A/G-agarose beads, washed three times with ice cold RIPA buffer, and
denatured with 2x Laemmli buffer for SDS-PAGE.

EGR1 Promoter Luciferase Reporter and Luciferase Assay. Luciferase
reporter assays were performed using a 2.1 kb fragment of the EGR1 promoter as
previously described (268). Briefly, luciferase assays were performed by transfecting EC
with EGR1-Promoter reporter 24 hours prior to treatment. Cells were lysed with passive
lysis buffer (Promega) and luciferase activity was assayed using the luciferase assay
system (Promega) according to the manufacturer’s instructions.

Quantitative Mass Spectrometry. After immunoprecipitation with an antiSTAT3 antibody (CST #9139), an ~86 kDa band was cut from Coomassie-stained gel,
digested with trypsin, and analyzed by capillary column LC-MS/MS to identify
phosphopeptides. The LC-MS/MS system were a Finnigan LTQ linear ion trap mass
spectrometer and a LTQ-Orbitrap Elite system. The HPLC column was a self-packed 9
cm x 75 µm id Phenomenex Jupiter C18 (LTQ) or a Dionex 15 cm x 75 µm id Acclaim
Pepmap C18 reverse phase capillary column (Orbitrap). The digest was analyzed in both
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a survey manner and a targeted manner. The survey experiments were performed using
the data dependent multitask capability of the instrument acquiring full scan mass spectra
to determine peptide molecular weights and product ion spectra to determine amino acid
sequence in successive instrument scans. These data were analyzed by using all CID
spectra collected in the experiment to search the human reference sequence database with
the search program Mascot. The targeted experiments involve the analysis of specific
STAT3 peptides including the phosphorylated and unmodified forms of the Y705, S727,
and T714 tryptic peptides. The chromatograms for these peptides were plotted based on
known fragmentation patterns and the peak areas of these chromatograms were used to
determine the extent of phosphorylation.

Protein Extraction from Tumor Tissue. Tumor tissue was procured from freshfrozen nephrectomies and an experienced kidney pathologist confirmed ccRCC or pRCC
diagnosis by histology. ~100 mg samples of tumor tissue were solubilized in RIPA buffer
supplemented with protease and phosphatase inhibitors using a dounce homogenizer, and
lysates were cleared once by high-speed centrifugation, tumbled end-over end overnight,
cleared again by centrifugation, after which STAT3 was immunoprecipitated using an
anti-STAT3 monoclonal antibody.

Development of Polyclonal Anti-Sera for STAT3 Thr714 Phosphorylation.
Anti-STAT3 P-Thr714 polyclonal anti-sera was generated by immunizing a rabbit with a
phosphorylated peptide corresponding to phosphorylation at that site (KFICVpTPTTC).
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In vitro kinase assays. Recombinant STAT3 was purchased form Abcam
(ab64310) and active GSK-3β was purchased from New England Biolabs (NEB P6040)
and utilized according to the manufacturer’s instructions. Briefly, STAT3 was incubated
with GSK-3β in ATP-supplemented kinase buffer (20 mM Tris-HCl pH 7.5, 10 mM
MgCl2, 5 mM DTT) for 1 hour at 30°C. For immune complex phosphorylation assays,
recombinant WT STAT3, T714A STAT3, and S727A STAT3 was expressed in EC by
transient transfection of STAT3 cDNAs. Prior to lysis, EC were serum starved for 2
hours to reduce STAT3 basal phosphorylation. EC were lysed and STAT3 was
immunopurified using an anti-STAT3 monoclonal antibody and protein A/G beads.
Beads were washed with RIPA buffer and resuspended in kinase buffer supplemented
with ATP in the absence or presence of GSK-3β for 1 hour at 30°C. Reactions were
terminated with 2x SDS buffer and analyzed by SDS-PAGE and immunoblot.

Chromatin Immunoprecipitation. Chromatin immunoprecipitations (ChIP)
were performed using a commercially available kit according to the manufacturer’s
instructions (Millipore, #17-295). Human EC treated with EGF plus TRAP or IL-6 for 15
minutes were cross-linked by the addition of formaldehyde. Cross-linked EC were lysed
in an SDS lysis buffer and sonicated using a sonicator 3000 (Misonix Inc, Farmingdale,
NY). Chromatin-protein complexes were immunoprecipitated overnight with an antiSTAT3 antibody, and genomic DNA was purified using DNA PrepEase columns
(Affymetrix). Purified genomic DNA was analyzed by quantitative real-time PCR using
primers flanking the upstream GAS element in the EGR1 promoter (268); forward
primer:

5’-CAGGAGGAGCCTTCCCTTCCCG-3’;
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reverse

primer:

5’-

CTGGGGCCGAACGCAACAG-3’. Data were normalized relative to the amount of
input DNA for each sample and expressed as the fold change relative to the untreated
control sample.

Statistical Analyses. Unless otherwise indicated, data are expressed as mean +/SEM. Differences between groups were analyzed by analysis of variance (ANOVA).
Bonferroni post-hoc tests were performed to calculate multiplicity adjusted p-values and
evaluate pairwise differences between groups. Differences between tumor and normal
tissue were evaluated by two-tailed paired t-tests. Significance is expressed as: *,p<0.05;
**,p<0.01; ***,p<0.001.

3.4

Results

Multiple STAT3 phosphoforms are induced by combinatorial EGFR/PAR-1
signaling in endothelial cells.
We previously showed that GSK-3α/β participate in STAT3 activation
downstream of simultaneous EGFR/PAR-1 signaling by positively regulating STAT3
Ser727 phosphorylation (Figure 46). STAT3 Thr714 is located in an evolutionarily
conserved region that includes conservation of proline in the +1 position, raising the
possibility that it is a direct substrate of GSK-3α/β. We therefore examined Thr714 and
Ser727 phosphorylation in EC by quantitative mass spectrometry (Table I). STAT3 was
immunoprecipitated from EC treated with EGF plus thrombin receptor agonist peptide
(TRAP), a PAR-1 activator. Immunoprecipitates were resolved by SDS-PAGE and ~86
kDa protein bands were cut from the gel for LC-MS/MS analysis. We readily detected
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phosphorylation of STAT3 at Thr714 or Ser727 (Figure 47). We also identified STAT3
phosphopeptides that were phosphorylated at both Thr714 and Ser727 (Figure 48).
Surprisingly, we failed to detect STAT3 Tyr705 phosphopeptides by mass spectrometry
under these conditions (Table I).

Figure 46. STAT3 is a potential GSK-3α/β substrate. Coincident PAR-1 activation prevents
EGF-induced inhibition of GSK-3α/β by AKT, thus allowing GSK-3α/β to positively regulate
Ser727 phosphorylation (268). As proline-directed kinases, GSK-3α/β may directly phosphorylate
both Thr714 and Ser727.

Table I. List of peptides targeted by LC-MS/MS. Serum-starved EC were treated with EGF
plus TRAP for 15 min., after which STAT3 was immunoprecipitated, and STAT3
phosphorylation was quantified by selected reaction monitoring targeting the specific STAT3
peptides listed in the table.
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Figure 47. Identification of singly phosphorylated STAT3 Thr714 and Ser727. The CID
spectrum of the singly phosphorylated form of the T710-729 STAT3 peptide,
FICVTPTTCSNTIDLPMoSPR. This spectra is consistent with the presence of two different
forms of the peptide. The y5 ion at 683.3 Da is consistent with phosphorylation at S727. The
presence of an unmodified y15 ion at 1705 Da and only a modified y16 ion at 1886 Da indicates
that a second isoform with modification at T714 is also present.

Figure 48. Identification of STAT3 phosphorylated at both Thr714 and Ser727. The CID
spectrum of the doubly phosphorylated form of the T710-729 STAT3 peptide,
FICVTPTTCSNTIDLPMoPR. The identification of the C-terminal y5 ion at 683 Da is consistent
with phosphorylation at Ser727. In addition, the mass difference between the y16 and y15 ions is
181 Da and is consistent with the second site of phosphorylation occurring at Thr714.
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Differential induction of STAT3 phosphoforms by EGFR/PAR-1 signaling.
We next sought to characterize signaling mechanisms regulating the inducible
formation of STAT3 phosphoforms. EC were stimulated with EGF plus TRAP for up to
one hour, STAT3 was immunoprecipitated and resolved by SDS-PAGE (Figure 49), and
the kinetics with which STAT3 phosphoforms are induced were analyzed by LC-MS/MS.
Singly phosphorylated Thr714 or Ser727 phosphoforms are induced as early as 5 minutes
following EGF plus TRAP treatment, and reach a maximum at ~15 minutes posttreatment (Figure 50, red and blue). Levels of Thr714-phosphorylated STAT3 and Ser727phosphorylated STAT3 begin to decrease after 15 minutes and stabilize at ~50% of their
maximum levels between 30-60 minutes after stimulation. Doubly phosphorylated
STAT3 exists in much lower abundance than singly modified phosphoforms (Figure 50,
green), but demonstrates the highest degree of stimulus-dependent inducibility (Figure
50). Further, the level of doubly phosphorylated STAT3 remains elevated up to 30
minutes after stimulus exposure, after which it returns to ~5 fold of the basal level
(Figure 50).

Figure 49. Immunoprecipitation of STAT3 for timecourse LC-MS/MS experiment. STAT3
was immunoprecipitated from the pooled extracts and resolved by SDS-PAGE. An ~86 kDa band
corresponding to Coomassie-stained STAT3 was cut from the gel, digested with trypsin, and
subjected to LC-MS/MS and selected reaction monitoring (SRM) to quantify specific STAT3
phosphoforms. This method allowed independently treated replicates to yield sufficient
endogenous STAT3 for LC-MS/MS analysis.
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Figure 50. Quantitative analysis of STAT3 phosphoforms in response to EGF plus TRAP.
(Left) Serum-starved EC were treated with EGF and TRAP for the indicated times, after which
they were lysed in RIPA buffer, and STAT3 was immunoprecipitated for mass spectrometry
analysis as described in materials and methods. 3 independently-treated 100 mm dishes were
pooled and used for each point indicated on the graph. % Phosphorylation was calculated as the
abundance of a specific phosphoform divided by the abundance of all STAT3 tryptic peptides at
that site. (Right) Data presented as fold-change relative to basal levels for each specific STAT3
phosphoform. Curve fit analyses were performed using a two-phase exponential model.

To determine the extent to which STAT3 phosphoforms are regulated by
EGFR/PAR-1 crosstalk, EC were treated with EGF, TRAP, or both for 15 minutes
(Figure 51) and STAT3 phosphoforms were measured by LC-MS/MS. Singly
phosphorylated Thr714 STAT3 was moderately induced by either EGF or TRAP alone,
and combination treatment caused an almost perfectly additive increase in pThr714
STAT3 abundance (Figure 52). Singly phosphorylated Ser727 STAT3 was also
moderately induced by either EGF or TRAP alone, and was synergistically induced by
combination treatment with EGF plus TRAP (Figure 52). Doubly phosphorylated STAT3
was undetectable during unstimulated conditions, and stimulation with either EGF or
TRAP caused a minimal increase in the abundance of this phosphoform (Figure 52).
Remarkably, combination treatment with EGF plus TRAP increased levels doubly
phosphorylated STAT3 in a manner that was strongly synergistic compared to the
response with either EGF or TRAP alone (Figure 52).
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Figure 51. Immunoprecipitation of STAT3 for LC-MS/MS analysis after combination
treatment with EGF and TRAP. Coomassie-stained polyacrylamide gel of STAT3
immunoprecipitates after treatment with EGF (16 ng/ml), TRAP (100 µM), or both for 15
minutes

Figure 52. Quantitative analysis of STAT3 phosphoform abundance during combinatorial
EGFR/PAR-1 signaling. Serum-starved EC treated with EGF, TRAP, or both for 15 minutes and
processed for quantitative mass spectrometry of Thr714 phosphorylation (blue), Ser727
phosphorylation (red), and doubly phosphorylated STAT3 (green) as in Figure 50. The
synergism
ratio
for
individual
STAT3
phosphoforms
was
calculated
as:
ResponseEGF+TRAP/(ResponseEGF+RespnseTRAP).
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EGF plus TRAP-induced STAT3 phosphorylation is distinct from IL-6-induced
phosphorylation.
Next, we sought to validate our mass spectrometry results for Thr714, Ser727, and
Tyr705 phosphorylation. STAT3 was immunoprecipitated from HUVEC and various
phospho-specific antibodies were used to assess the levels of distinct STAT3
phosphorylations.

To

investigate

stimulus-inducible

Thr714

phosphorylation

by

immunoblot, a polyclonal STAT3 anti-pThr714 antibody was generated by immunizing a
rabbit with a phosphopeptide corresponding to the STAT3 residues at that phosphosite.
STAT3 Thr714 phosphorylation was synergistically induced in response to 15 minute EGF
plus TRAP treatment (Figure 53). Ser727 phosphorylation was also synergistically
induced when STAT3 immunoprecipitates were probed with an anti Pro-Met-pSer-Pro
motif (PMpSP) antibody that is designed to recognize phosphorylated serine in the MAP
kinase consensus motif corresponding to Ser727 (Figure 53). We previously showed that a
commercially available pSer727 STAT3 antibody recognizes synergistically induced
Ser727 phosphorylation in a manner consistent with mas spectrometry results after 5
minute stimulation with EGF plus TRAP (268). However, after 15 minute stimulation,
the commercial antibody does not reflect the ~8-10 fold induction of Ser727
phosphorylation that occurs (as indicated by mass spectrometry and PMpSP antibody),
possibly due to the increased abundance of cooperating modifications near that site
(Figure 53). Therefore, in subsequent experiments, we used immunoprecipitation and
anti-PMpSP immunboblots to assess Ser727 phosphorylation.
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Figure 53. Antibody standardization for synergistic Thr714 and Ser727 phosphorylation.
Serum-starved EC were treated with EGF, TRAP, or both for 15 minutes, and STAT3 was
immunoprecipitated and resolved by SDS-PAGE. STAT3 phosphorylations were assessed by
immunoblot. The anti-pThr714 antibody was generated by immunizing a rabbit with a
phosphorylated peptide corresponding to phosphorylation at that site (KFICVpTPTTC). STAT3
Ser727 phosphorylation was detected using a Pro-Met-phospho-Ser-Pro motif antibody and a
commercially available antibody form Santa Cruz Biotechnology. Densitometry analysis of Thr714
and Ser727 phosphorylation was performed from 3 independent experiments.

We next sought to standardize immunoblotting methods for detecting multiple
STAT3 phoshorylations. Our mass spectrometry results suggested that phosphorylation
of STAT3 Tyr705 is low or absent in EC. To validate this result, we performed a doseresponse experiment using increasing levels of EGF in the presence of TRAP and
analyzed Tyr705 phosphorylation by immunoblot using three commercially available
antibodies (Figure 54). Tyr705 phosphorylation was strongly induced by IL-6, but not by
EGF plus TRAP, even at high EGF concentrations. Basal Tyr705 phosphorylation was
detectable upon overexposure of the film, suggesting that this modification occurs basally
at very low abundance in EC. A commercially available pSer727 antibody did not detect a
strong EGF plus TRAP induced phosphorylation at Ser727, suggesting that there is a loss
of affinity of the antibody for phosphorylated STAT3 at this timepoint (Figure 54). EGF
plus TRAP stimulation increased Thr714 phosphorylation and PMpSP phosphorylation
(Ser727) of STAT3 at all concentrations (Figure 54).
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Figure 54. Dose-response analysis of STAT3 Tyr705 phosphorylation. Serum-starved EC were
treated with EGF at the indicated concentration in the presence of TRAP for 15 minutes. EC were
lysed with RIPA buffer and STAT3 was immunoprecipitated and resolved by SDS-PAGE. Three
antibodies (Ab.) were used to assess Tyr705 phosphorylation. Ab. 1 is Cell Signaling Technology
(CST) #9131, Ab. 2 is CST #9145, and Ab. 3 is CST #9138. The immunoblot with CST #9138
was deliberately overexposed to film to detect basal STAT3 Tyr705 phosphorylation. Thr714 and
Ser727 phosphorylation were assessed as in Figure 53. PMpSP antibody is used to target Ser727
phosphorylation, as the pSer727 antibody (Santa Cruz) does not recognize phosphorylated Ser727 in
a manner consistent with mass spectrometry data at this timepoint. IL-6 (10 ng/ml) was included
as a positive control for Tyr705 phosphorylation.

GSK-3α/β phosphorylate STAT3 to generate a doubly modified phosphoform.
We previously reported that GSK-3α/β positively regulated STAT3 Ser727
phosphorylation and STAT3-dependent gene expression in EC (268). Therefore, we
investigated the extent to which GSK-3α/β regulates the stimulus-inducible generation of
specific STAT3 phosphoforms downstream of EGFR/PAR-1 signaling. Depletion of
GSK-3α/β by RNAi caused a 90% decrease in the levels of inducible doubly
phosphorylated STAT3, while causing only a partial reduction in single pThr714 or
pSer727 STAT3 (Figure 55). This result was verified by immunoblotting STAT3
immunoprecipitates using a STAT3 pThr714 antibody (Figure 56) and by anti-pThr-Pro
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and Pro-Met-pSer-Pro motif antibodies to detect the levels of pThr714 and pSer727,
respectively (Figure 57). In all cases, GSK-3α/β depletion caused a reduction in total
pThr714 and pSer727, demonstrating GSK-3α/β positively regulate STAT3 Ser/Thr
phosphorylation. Moreover, this result demonstrates that there are both GSK-3α/βdependent and GSK-3α/β-independent components of STAT3 Thr714 and Ser727
phosphorylation, and GSK-3α/β are required for generating doubly phosphorylated
STAT3 in this context.

Figure 55. GSK-3α/β-dependent generation of STAT3 phosphoforms. GSK-3α/β were
depleted from EC by RNAi. 48 hours after siRNA transfection, EC were stimulated with EGF
plus TRAP for 15 minutes and STAT3 phosphoform abundance was analyzed by mass
spectrometry. pThr714 is indicated by blue bars, pSer727 by red bars, and pThr714/pSer727 by green
bars.

106

Figure 56. Immunoblot analysis of GSK-3-dependent STAT3 Thr714 phosphorylation. GSK3α/β were depleted from EC by RNAi, and the effect on EGF+TRAP-induced STAT3 Thr714
phosphorylation was analyzed by immunoblots of STAT3 immunoprecipitates using anti-STAT3
pThr714 polyclonal anti-sera.

Figure 57. Immunoblot analysis of GSK-3-dependent STAT3 serine/threonine
phosphorylation. GSK-3α/β were depleted from EC by RNAi, and the effect on EGF+TRAPinduced STAT3 Thr714 phosphorylation was analyzed by immunoblots of STAT3
immunoprecipitates using anti-Thr-Pro and anti-Pro-Met-pSer-Pro motif antibodies. The amino
acid sequence under the immunoblot represents STAT3 710-729 and indicates the sites targeted
for immunodetection. Densitometry values represent quantification of 3 independent
immunoblots.
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GSK-3β efficiently phosphorylated STAT3 in vitro at a pThr-Pro site (Figure 58).
To test the ability of GSK-3β to phosphorylate STAT3 at Thr714 and Ser727, we
immunopurified WT STAT3, S727A STAT3, and T714A STAT3 for use as in vitro
GSK-3β substrates. GSK-3β efficiently phosphorylated both Thr714 and Ser727 (Figure
59). Mutation of Ser727 to alanine dramatically reduced the ability of GSK-3β to
phosphorylate Thr714. In contrast, mutation of Thr714 to alanine did not affect Ser727
phosphorylation by GSK-3β (Figure 59), suggesting that Ser727 may regulate priming or
processive phosphorylation of STAT3 Thr714 by GSK-3α/β.

Figure 58. GSK-3β directly phosphorylates STAT3. In vitro kinase assay using recombinant
GSK-3β (New England Biolabs) and STAT3 (Abcam) substrate was performed for 1 hour at
30°C, and threonine phosphorylation was detected using a pThr-Pro motif antibody.
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Figure 59. Phosphorylation of STAT3 Thr714 by GSK-3β requires Ser727. Endogenous STAT3
was depleted by RNAi targeting the 3’UTR of STAT3, and recombinant WT-STAT3, S727A
STAT3, or T714A STAT3 was immunopurified from serum-starved EC and used as an in vitro
substrate for GSK-3β. The amino acid sequence under the immunoblot represents STAT3 710729 and indicates the sites targeted for immunodetection.

STAT3 phosphorylation at Thr714 by GSK-3α/β positively regulates target gene
expression.
We previously showed that simultaneous EGFR/PAR-1 activation causes
synergistic induction of EGR1 in a manner that requires STAT3 Ser727 phosphorylation
(268). To identify established STAT3 targets that are regulated by EGFR/PAR-1
signaling, we examined Bcl2 family members that are known to require STAT3 Ser727
phosphorylation, including Mcl1 (187). Indeed, we found that EGF plus TRAP
maximally induced Mcl1 at two hours post-treatment (Figure 60), and this induction was
synergistic compared to treatment with either EGF or TRAP alone (Figure 61).
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Figure 60. Timecourse of Mcl1 induction in response to EGF plus TRAP. Serum-starved EC
were treated with EGF plus TRAP over a timecourse of up to 8 hours and inducible Mcl1
expression was analyzed by immunoblot.

Figure 61. Synergistic induction of Mcl1 in response to EGF plus TRAP. Serum starved EC
were treated for 2 hours with EGF, TRAP, or both and Mcl1 expression was analyzed by
immunoblot. Densitometry analysis (right) represents the quantification of 3 independent
immunoblots.

Depletion of STAT3 by RNAi completely inhibited synergistic induction of Mcl1
(Figure 62), demonstrating that STAT3 is critical for EGFR/PAR-1 crosstalk, consistent
with our previously published results for EGR1 induction (268). Inducible expression of
Mcl1 was reduced ~50% when GSK-3α/β were depleted by RNAi, consistent with our
hypothesis that GSK-3α/β positively regulate STAT3 activity (Figure 63).
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Figure 62. Synergistic induction of Mcl1 requires STAT3. STAT3 was depleted by RNAi and
EC were treated with EGF, TRAP, or both for two hours and Mcl1 expression was analyzed by
immunoblot.

Figure 63. GSK-3α/β are required for Mcl1 induction by EGF plus TRAP. GSK-3α/β were
depleted from EC by RNAi, and the effect on Mcl1 induction was analyzed by immublot.
Densitometry values represent the quantification of 4 independent experiments.
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Further, WT STAT3, but not T714A, S727A, or T714A/S727A STAT3 mutants,
rescued EGF plus TRAP induced Mcl1 expression when endogenous STAT3 was
depleted by RNAi (Figure 64). In contrast, a STAT3 Y705F mutant lacking the canonical
phosphorylation site rescued Mcl1 induction to a similar extent as WT STAT3,
suggesting that combinatorial activation of STAT3 by EGFR/PAR-1 is Tyr705independent (Figure 65).

Figure 64. STAT3 Thr714 and Ser727 are required for Mcl1 induction in response to EGF
plus TRAP. Endogenous STAT3 was depleted by RNAi with siRNA targeting 3’UTR, and
STAT3 levels were reconstituted by transient expression of recombinant WT, T714A, S727A, or
T714A/S727A STAT3, and the effect on Mcl1 expression was analyzed by immunoblot.
Densitometry values represent quantification of 6 independent experiments for the GFP/control,
GFP/siSTAT3, WT/siSTAT3, and T714A/siSTAT3 and 3 experiments for S727A and
T714A/S727A STAT3. Statistical analyses were performed using a one-way ANOVA.
Multiplicity adjusted p-values were used to determine significant differences from WT STAT3
rescue.
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Figure 65. EGF plus TRAP-induced Mcl1 expression is Tyr705-independent. Experiment
performed as in Figure 64 using a Y705F STAT3 mutant. Densitometry values represent
quantification of 3 independent experiments. Multiplicity adjusted p-values were used to
determine significant differences from WT STAT3 rescue.

Simultaneous EGFR/PAR-1 signaling induces STAT3 binding to a distal GAS
element in the EGR1 promoter.
We next sought to compare combinatorial activation of STAT3 by EGF plus
TRAP to canonical activation of STAT3 by IFNγ or IL-6. Simultaneous EGFR/PAR-1
activation strongly induced STAT3 Thr-Pro and Thr714 phosphorylation at 15 minutes
(Figure 66). A PMpSP motif antibody (Ser727) detected phosphorylated STAT3 Ser727 in
a manner largely consistent with data from mass spectrometry experiments (Figure 66).
Neither IL-6 nor IFNγ induced a significant degree of STAT3 threonine phosphorylation.
IL-6 and IFN-γ, but not EGF plus TRAP, strongly induced STAT3 Tyr705
phosphorylation, suggesting that STAT3-dependent gene expression can be triggered by
EGF plus TRAP in the absence of Tyr705 phosphorylation. Further, we previously showed
that an upstream GAS element in the EGR1 promoter was critical for EGF plus TRAP
induced promoter activation (268). EGF plus TRAP, but not IL-6, induced STAT3
binding to this upstream promoter region (Figure 67).
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Figure 66. EGF plus TRAP induced STAT3 phosphorylation is distinct form IL-6 or IFNγinduced phosphorylation. Serum-starved EC were treated with EGF plus TRAP, IFNγ (10
ng/ml), or IL-6 (10 ng/ml) for 15 min. after which STAT3 was immunoprecipitated and
phosphorylations were analyzed by immunoblot.

Figure 67. EGF plus TRAP treatment induces STAT3 binding to the EGR1 promoter. EC
were stimulated for 15 min with EGF plus TRAP or IL-6, after which STAT3 was
immunoprecipitated from cross-linked cell extracts. DNA was isolated from immunoprecipitates
and EGR1 promoter was PCR amplified using forward and reverse primers flanking the upstream
GAS element of the EGR1 promoter. Binding of STAT3 to EGR1 promoter was verified by DNA
sequencing of PCR amplicons.
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Additionally, when EC were cotransfected with an EGR1 promoter reporter,
EGR1 promoter activation was significantly reduced by cotransfection with T714A
STAT3 relative to WT STAT3 (Figure 68). Coupled with our previous results, these data
demonstrate that both Thr714 and Ser727 are required for maximal EGR1 promoter
activation (268). Overexpression of a phosphomimetic T714D STAT3 mutant was not
sufficient to increase basal EGR1 promoter activity relative to WT STAT3 (Figure 68),
suggesting that other modifications and signaling pathways are required. To test the
requirement of Tyr705 in EGR1 promoter activation, we overexpressed WT STAT3 or
Y705F STAT3 in STAT3-depeleted EC and measured EGR1 promoter activity in
response to EGF plus TRAP. EGF plus TRAP induced promoter activation was similar
for WT STAT3 and Y705F STAT3 (Figure 69).

Figure 68. STAT3 Thr714 phosphorylation is required but not sufficient for EGR1 promoter
activation. (Left) EC were co-transfected with an EGR1 promoter reporter and WT-STAT3 or
T714A STAT3. EGF+TRAP induced luciferase activity was measured after 4 hour treatment
using a luminometer. Data represent the values from 5 independent experiments. Endogenous
STAT3 was depleted by siRNA targeting the 3’UTR of STAT3 in all conditions. (Right) EC were
co-transfected with an EGR1 promoter reporter and WT-STAT3 or T714D STAT3. Basal
luciferase activity was measured after 8 serum-starvation using a luminometer. Data represent the
mean +/- SEM from 3 independent experiments.
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Figure 69. EGF plus TRAP-induced EGR1 promoter activation is STAT3 Tyr705independent. EC were co-transfected with an EGR1 promoter reporter and WT-STAT3 or
Y705F STAT3. EGF+TRAP induced luciferase activity was measured after 4 hour treatment
using a luminometer. Data represent the mean +/- SEM from 3 independent experiments.

Doubly phosphorylated STAT3 is elevated in human renal tumors.
Preclinical studies of renal cell carcinoma (RCC) have validated both STAT3 and
GSK-3α/β as targetable molecules for the therapeutic inhibition of RCC progression
(209, 270–272). Additionally, aberrant nuclear accumulation of GSK-3β has been
reported to occur in >90% of human RCC cases. Based on these studies and our
discovery of a direct link between GSK-3α/β and STAT3 Thr714 phosphorylation, we
hypothesized that doubly phosphorylated STAT3 may be elevated in renal tumors. We
analyzed STAT3 PTMs in a cohort of 4 clear cell RCC (ccRCC) and 4 papillary RCC
(pRCC) patients to determine the relative degree of STAT3 Thr714 phosphorylation in
these cases. Thr714 phosphorylation was detectable in all patients by immunoblot, but was
remarkably elevated in 2/4 ccRCC cases and 1/4 pRCC cases (Figure 70). STAT3 Ser727
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phosphorylation (anti-PMpSP) was elevated in 4/4 ccRCC cases and 1/4 pRCC cases.
STAT3 pTyr705 was elevated in 4/4 ccRCC patients and 1/4 pRCC patients.

Figure 70. Immunoblot analysis of STAT3 phosphorylation in renal cell carcinoma. Human
renal tumor samples (clear cell and papillary) were isolated from tissue after nephrectomy. Tumor
tissue was solubilized in RIPA buffer, cleared by high-speed centrifugation, and STAT3 was
immunoprecipitated overnight. Half of the immunoprecipitate was analyzed by immunoblot to
confirm the presence of STAT3 and its phosphorylations. Recombinant (Rec.) STAT3 was
included as a non-phosphorylated reference.
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The same cases were analyzed by LC-MS/MS to measure the abundance of
STAT3 phosphoforms (Figure 71). STAT3 phosphoform abundance was generally
elevated in ccRCC vs. pRCC and levels of pSer727 and pTyr705 were significantly elevated
in ccRCC (Figure 71).

Figure 71. Quantitative LC-MS/MS analysis of STAT3 phosphoform abundance in renal
cell carcinoma. The remaining immunoprecipitates from experiments in Figure 70 were
processed by LC-MS/MS to measure the abundance of STAT3 phosphoforms in these tumors.
“Double” phosphorylation represents STAT3 that is simultaneously phosphorylated at Thr714 and
Ser727. Horizontal bars represent the median of each group. The Mann-Whitney U test was used to
evaluate significantly different means.

Based on these results, we procured 10 additional cases of ccRCC with matched
normal tissue to determine the extent to which STAT3 phosphoform abundance differed
in tumor tissue relative to adjacent normal tissue. Singly phosphorylated STAT3 at Thr714
or Ser727 was significantly elevated in tumor tissue relative to adjacent normal tissue
(Figure 72). Doubly phosphorylated STAT3 was also significantly more abundant in
tumor tissue, indicating that the GSK-3α/β-STAT3 signaling may be active in ccRCC
(Figure 72). In contrast, pTyr705 STAT3 displayed a high degree of variability and was
not significantly different between normal and tumor tissue (Figure 72).

118

Figure 72. Quantitative analysis of STAT3 phosphoform abundance in renal tumors vs.
normal tissue. 10 cases of ccRCC and patient-matched normal tissue were examined by
microscopy to confirm diagnosis and estimate the number of tumor nuclei per field. Tumor tissue
and matched tissue controls were solubilized as in Figure 70, and STAT3 was
immunoprecipitated to analyze phosphoform abundance by LC-MS/MS. Two-tailed paired t-tests
were used to evaluate statistical significance.

To examine the relative contribution of cancer cells vs. stromal cells to tumorassociated STAT3 phosphorylation, we examined the extent to which STAT3
phosphoforms correlated with the percentage of tumor nuclei in ccRCC cases. pThr714
and doubly phosphorylated STAT3 exhibited a positive correlative trend vs. the
percentage of tumor nuclei in each sample, but this relationship was not statistically
significant (Figure 73). Neither pSer727 nor pTyr705 correlated with the percentage of
tumor nuclei (Figure 73). These data clearly demonstrate that Thr714 and Ser727phosphorylated STAT3 are elevated in renal tumor tissue, suggesting that GSK-3α/βSTAT3 signaling is a novel targetable signaling axis in ccRCC.
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Figure 73. Correlation analysis of STAT3 phosphoform abundance vs. percentage of tumor
nuclei in tumor samples. An experienced kidney pathologist estimated the percentage of tumor
nuclei per field. Pearson correlation coefficients were calculated based on percentage of tumor
nuclei (x-axis) vs. phosphoform abundance (y-axis). Pearson r-values and two-tailed p-values for
correlation with tumor nuclei were: pThr714 (r = .37, p = .29); pSer727 (r = -.42, p = .23); Double
pSTAT3 (r = .44, p = .20); pTyr705 (r = -.38, p = .28).

3.5

Discussion
The transcriptional activity of STAT3 is modulated by reversible PTMs that

regulate dimerization, DNA-binding, and protein-protein interactions. Activated STAT3,
in turn, transcriptionally activates genes that promote growth and survival, and is thought
to be a major driver of solid tumor progression. We now report that STAT3 Thr714 is
phosphorylated in addition to Ser727 in response to EGF signaling during coincident
GPCR activation, and both of these modifications are critical for STAT3-dependent
expression of Mcl1 and EGR1 (Figure 64, 68). Therefore, the data herein strongly
suggest that EGR1 and Mcl1 induction is driven by a low abundant but dynamically
regulated STAT3 phosphoform that is simultaneously modified at Thr714 and Ser727,
likely in the absence of Tyr705 phosphorylation (Table I, Figure 48, 54, 66). Further, our
data demonstrate that GSK-3α/β exclusively mediate the generation of doubly
phosphorylated STAT3 to induce Mcl1 and EGR1 during coincident EGFR/PAR-1
activation (Figure 55, 59). The additive response of pThr714 STAT3 to EGF plus TRAP
(Figure 52), and the observation that T714A does not affect Ser727 phosphorylation
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(Figure 59), suggests that there is little to no conversion of pThr714 STAT3 to doubly
phosphorylated STAT3 in this context (Figure 74). We therefore propose that doubly
phosphorylated STAT3 mediates a noncanonical mechanism of STAT3 activation that is
triggered specifically by combinatorial EGFR/PAR-1 signaling and is aberrantly
regulated in human renal tumors (Figure 74).

Figure 74. Model of GSK-3α/β-dependent STAT3 phosphorylation. Model showing the
inducible flux of STAT3 phosphoforms stimulated with different combinations of EGF plus
TRAP. Simultaneous EGFR/PAR-1 activation is required to drive significant formation of doubly
phosphorylated STAT3 and STAT3-dependent gene expression in this context. Furthermore,
GSK-3α/β are required for nearly all of the doubly phosphorylated STAT3 generated following
EGFR/PAR-1 activation (red panel). During individual activation of EGFR or PAR-1, or in the
absence of GSK-3α/β, STAT3 is inducibly phosphorylated at Thr714 or Ser727 (blue panel).
Numerous Ser727 kinases are known, but there likely exists additional proline-directed Thr714
kinases that catalyze single phosphorylation of Thr714 in the absence of GSK-3α/β and Ser727
phosphorylation.
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STAT3 Thr714 phosphorylation adds to the high frequency of PTMs within a
relatively small region of the STAT3 COOH terminus.

Between Lys679 and Ser727

researchers have identified acetylation of Lys679, Lys685, Lys707, Lys709 (166–169), and
phosphorylation at Tyr705, Thr714, and Ser727 (123, 159). The mechanisms by which
canonical STAT3 modifications (pTyr705 and pSer727) regulate STAT3 function are
relatively clear. However, the exact mechanisms by which lysine acetylation/methylation
and threonine phosphorylation regulate transcriptional activity of STAT3 are not well
understood, and more work is required to understand the structural basis for promoterspecific functions of individual STAT3 PTMs. In any event, the diversity and abundance
of STAT3 PTMs that is now reported, coupled with the established functions of
unphosphorylated STAT3 (U-STAT3) (174, 175, 181), demonstrate that Tyr705
phosphorylation is neither necessary nor sufficient for STAT3 activation in a number of
signaling contexts (175, 179, 181, 186, 188, 210). Further, STAT1/3 phosphorylations at
Tyr701/705 and Ser727 are often mediated by the same kinases, as the sequences
surrounding these residues are highly similar. However, the amino acids surrounding
Ser708 in STAT1 and Thr714 in STAT3 are unique, suggesting a possible basis for the
differential activation of STAT1/3 via regulation of distinct proximal kinases. In support
of this notion, others have shown that IKKε phosphorylates STAT1 Ser708 to regulate
anti-viral immunity (273, 274), and we now present evidence that STAT3 Thr714 is
mediated by GSK-3α/β to positively regulate Mcl1 and EGR1 expression.

It is known that STAT3 can dimerize in the absence of Tyr705 phosphorylation
(174). Furthermore, recent studies using both atomic force microscopy and x-ray
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crystallography have directly visualized U-STAT3 binding to GAS elements as an
unphosphorylated dimer (175, 176). Our results suggest that STAT3 binds to an upstream
GAS element in the EGR1 promoter in the absence of Tyr705 phosphorylation.
Interestingly, others have shown that oncostatin M induces STAT3 Tyr705
phosphorylation and STAT3 binding to the EGR1 promoter within 30 minutes of
stimulation (275). However, the same study also showed that IFNγ strongly induces
STAT3 Tyr705 phosphorylation but does not elicit STAT3 binding to the EGR1 promoter,
consistent with our results for IL-6 (Figure 66, 67). Although direct promoter binding of
Tyr705-phosphorylated STAT3 was not tested in that study, our results raise the
possibility that canonical and noncanonical mechanisms of STAT3 activation converge
on common GAS elements to regulate transcription. This is in agreement with structural
studies that suggest U-STAT3 and Tyr705-phosphorylated STAT3 bind to the same DNA
elements (176, 276).

The identification of doubly phosphorylated STAT3 in human RCC indicates that
the GSK-3α/β-STAT3 axis may be active in a subset of human tumors. The multi-kinase
inhibitors sorafenib and sunitinib are approved for use in RCC patients, and it is thought
that their major mechanism of action is through the inhibition of angiogenesis (277, 278).
Sorafenib and sunitinib effectively prolong progression free survival (279, 280), but
resistance to these drugs invariably limits their efficacy, and mechanisms of resistance
are poorly defined (281). It was recently reported that sorafenib treatment increased
GSK-3β activity in RCC cells, and that combination therapy of sorafenib plus GSK-3α/β
inhibitors synergistically inhibited xenograft tumor growth in a mouse model of RCC
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(272). Additionally, aberrant nuclear accumulation of GSK-3β is reported to occur in
>90% of RCC cases (271), and an immunohistochemistry analysis of renal tumors
showed that tyrosine phosphorylated nuclear STAT3 is present in approximately 60% of
ccRCC and pRCC cases (208). Importantly, a STAT3 inhibitor reduced tumor-associated
angiogenesis in a mouse model of RCC, and sunitinib-induced RCC cell apoptosis is
thought to be mediated in part via inactivation of STAT3 (209, 270).

The previous studies of STAT3 in RCC emphasized the role of pTyr705 as an
indicator of STAT3 activation in renal tumors. Our results suggest that Tyr705
phosphorylation is not significantly elevated in ccRCC, and Thr714 and Ser727
phosphorylation may be reliable predictors of GSK-3α/β-STAT3 signaling in this
disease. Similar results for STAT3 have been reported in peripheral blood cells of
patients with chronic lymphocytic leukemia (CLL). Hazan-Halavy et al. reported that
STAT3 is constitutively phosphorylated at Ser727, but not Tyr705, in this disease (186).
Furthermore, Ser727-phosphorylated STAT3 that was isolated from peripheral blood cells
of CLL patients bound DNA in the absence of Tyr705 phosphorylation (186). STAT3 also
facilitates Ras-dependent malignant transformation in a Tyr705-independent manner by
localizing to mitochondria and regulating the activity of the electron transport chain
(282). Yet another study used a phosphomimetic STAT3 mutant in which Ser727 was
substituted with glutamate (S727E) to show that Ser727 phosphorylation increases prostate
cancer cell tumorigenicity and invasive capacity (188). Importantly, a STAT3 double
mutant (Y705F/S727E) behaved similarly to the S727E condition, suggesting that the
tumorigenic effects of STAT3 Ser727 phosphorylation are Tyr705-independent in a prostate
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cancer cell line (188). Our own results demonstrate that singly phosphorylated Ser727
STAT3 is more abundant than doubly phosphorylated Thr714/Ser727 STAT3 in EC and
ccRCC. One possible explanation for this difference is that Ser727-phosphorylated STAT3
exists in higher abundance due to its dual role as a transcriptional regulator and
modulator of oxidative respiration.

Our results describe a novel mechanism of signal integration in which
combinatorial EGFR/PAR-1 signaling regulates a GSK-3α/β-STAT3 signaling axis.
Direct, multisite phosphorylation of STAT3 by GSK-3α/β therefore serves as the
molecular conduit through which temporal information of coincident receptor activation
is transduced to regulate gene expression in a strict combinatorial manner. This is the first
report that Thr714 phosphorylation regulates STAT3 function, and the data herein reveal a
new opportunity for the therapeutic inhibition of STAT3 transcriptional activity
downstream of an oncogenic receptor tyrosine kinase.
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CHAPTER IV

GENERAL DISCUSSION AND FUTURE DIRECTIONS

We have discovered a novel mechanism of STAT3 activation that is mediated by
direct phosphorylation of STAT3 at Ser727 and Thr714 by GSK-3α/β. This mechanism is
triggered in endothelial cells when EGFR and PAR-1 are simultaneously activated.
Further, it appears that the temporal spacing of EGFR and PAR-1 activation is “sensed,”
in part, via the opposed actions of EGFR and PAR-1 on the PI3K-AKT signaling axis.
EGFR signaling strongly activates AKT to inhibit GSK-3α/β-STAT3 signaling, but
concurrent PAR-1 activation prevents AKT-dependent inhibition of GSK-3α/β, thereby
permitting GSK-3α/β-mediated phosphorylation of STAT3 and STAT3-dependent gene
expression. Overall, our results reveal that biologically consequential signaling axes may
not be evident from simply studying “one ligand, one receptor” pathways, and careful
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consideration should be paid to the nuances of signaling interactions elicited by
simultaneously exposing cells to disparate extracellular stimuli.

Figure 75. Combinatorial activation of STAT3 by EGF and thrombin. Simultaneous
activation of EGFR/PAR-1 is required for STAT3-dependent immediate early gene expression.
EGFR signaling activates the PI3K-AKT signaling axis causing AKT-dependent phosphorylation
and inhibition of GSK-3α/β. Coincident PAR-1 signaling inhibits AKT activation in a Gα12/13dependent manner, preventing GSK-3α/β phosphorylation. GSK-3α/β phosphorylate STAT3 at
Thr714 and Ser727 to generate a doubly modified STAT3 phosphoform. Phosphorylation of both
Thr714 and Ser727 are required for induction of Mcl1 and EGR1 in this context. Furthermore,
STAT3 Tyr705 phosphorylation is low or absent in response to concentrations of EGF that elicit
gene induction, and is not required for STAT3-dependent gene induction in response to EGF plus
TRAP.

The expression of EGFR on endothelial cells has been disputed, as discussed in
chapter II. We invariably observe EGFR expression in HUVEC, and the data herein
demonstrate conclusively that HUVEC respond to EGF. The expression of EGFR in
primary endothelial cells may vary between culture conditions after isolation and
passage. However, given that others and we have demonstrated EGFR expression in
HUVEC, and others have shown that EGFR is expressed in MVEC, the role of
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endothelial EGFR warrants further investigation to more fully characterize its
physiological significance.

Anti-VEGF therapy is commonly used to inhibit pathological angiogenesis. Drugs
such as bevacizumab (Avastin ®) and aflibercept (Eyelea ™) act as VEGF-A scavengers,
and are used to inhibit tumor-associated angiogenesis and to treat age-related macular
degeneration (283). Although it is clear that VEGF is a potent stimulator of angiogenesis,
it is possible, if not likely, that EGF acts as a functionally redundant growth factor in
angiogenic microenvironments, thereby bypassing the requirement of VEGF for
neovascularization. Indeed, EGF stimulates angiogenesis to the same degree as VEGF in
the mouse cornea, suggesting that endothelial EGFR signaling may play an important
role in this process (140). It is well established that anti-EGFR drugs inhibit tumor
associated angiogenesis, but the scientific consensus has been that this effect is an
indirect consequence of decreased VEGF production in cancer cells which causes
endothelial cell apoptosis within the tumor (284–288). Recent results from our laboratory
and others’ suggest that anti-EGFR therapies likely have direct effects on endothelial cell
function (84, 140, 141, 289), and may exert anti-angiogenic responses independent of the
inhibitors’ actions on tumor cells (140).

GPCR-RTK signaling interactions have long been studied in the context of
“inside-out” transactivation (Figure 5). Our results do not conflict with these reports, but
they raise important questions regarding the specificity of RTK signaling following direct
activation vs. transactivation. Coincident GPCR signaling from receptors like PAR-1 may
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modulate RTK-dependent pathways such that transactivated RTK signaling is distinct
from direct activation of the RTK per se. In the case of EGFR and PAR-1, PAR-1
activation drastically inhibits the ability of EGFR to activate AKT (Figure 28). Others
have reported a similar phenomenon in the context of insulin receptor (IR) crosstalk with
angiotensin II-activated signaling pathways (290). Maeno et al. reported that activation of
PKC by angiotensin II led to phosphorylation and inhibition of PI3K, thus preventing
insulin-dependent activation of AKT in endothelial cells (290). Our results suggest that
PAR-1 coupling to Gα12/13 is critical for inhibition of EGF-induced AKT activation, and
others have shown that angiotensin II also couples to Gα12 and Gα13 (291). It is therefore
interesting to consider the possibility that PKC activation downstream of PAR-1 and
Gα12/13 may be responsible for modulating PI3K-AKT activation in the context of both
EGFR/PAR-1 and IR/angiotensin II crosstalk.

The activation of GSK-3α/β-STAT3 signaling requires the simultaneous presence
of extracellular EGF and thrombin. EGF and thrombin likely cooperate in the
microenvironment of diseases such as atherosclerosis and advanced cancers. For
example, it is known that infiltrating immune cells deliver significant amounts of EGF
and other growth factors to the hypoxic microenvironment of solid tumors (292, 293).
Macrophages are believed to promote tumor progression and metastasis in part via the
synthesis and secretion of growth factors including EGF (294). Thrombin and EGFfamily ligands are also found in atherosclerotic lesions in humans (295, 296), and
receptors for both thrombin and EGF are expressed on multiple cell types associated with
atherogenesis including smooth muscle cells, endothelial cells, and macrophages.
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Furthermore, efficient wound healing following tissue injury requires localized
inflammation, cellular migration, and proliferation. Both thrombin and EGF family
ligands are generated at sites of injury (297, 298), and neovascularization is a critical step
for the regeneration of functional tissues (299). It is possible that EGFR/PAR-1 crosstalk
controls endothelial activation following tissue injury to enhance the rate of wound
healing in a STAT3-dependent manner. Future studies in our laboratory will therefore
investigate the role of GSK-3α/β-STAT3 signaling in a mouse model of wound healing,
and evaluate the extent to which administration of EGF and TRAP may therapeutically
enhance wound closure.

We have focused on the cooperation of EGFR and PAR-1 to trigger noncanonical
STAT3 activity. However, it is important to note that our results may not be limited to
these specific receptors. GPCRs are the most abundant transmembrane receptor in the
human genome (86), and many GPCRs couple to similar sets of heterotrimeric Gproteins. It is possible that other receptors also synergize with EGFR by activating
STAT3 in a GSK-3α/β-dependent manner. In support of this idea, we previously showed
that LPA also induces synergistic expression of MKP-1 in endothelial cells treated with
EGF (84). Future work in our laboratory will therefore investigate other potential GPCRs
that activate STAT3 in cooperation with EGFR. Further, we will investigate the specific
structural and functional properties of GPCRs that confer the ability to modulate EGFactivated PI3K-AKT and STAT3 pathways.
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Our results have revealed a mechanism of STAT3 activation that likely occurs in
the absence of STAT3 Tyr705 phosphorylation. Others have shown numerous ways in
which STAT3 functions in the absence of tyrosine phosphorylation including DNAbinding, dimerization, and activating gene transcription (175, 176, 179). We have shown
that STAT3 binds to an upstream GAS element in the EGR1 promoter, but we have also
discovered that GSK-3α/β is a targetable kinase to inhibit STAT3-dependent gene
expression in this context. It is important to note that although our initial results suggest a
moderate increase in STAT3 Tyr705 phosphorylation in response to EGF, these
experiments were performed with high concentrations of EGF (50 ng/ml). At lower
concentrations (16 ng/ml), EGF treatment still synergizes with PAR-1 and induces
STAT3 Thr714 and Ser727 phosphorylation in a GSK-3α/β-dependent manner. However,
STAT3 Tyr705 phosphorylation is undetectable by mass spectrometry at this lower EGF
concentration, and western blot analysis of STAT3 immunoprecipitates shows no EGF
plus TRAP-dependent increase in STAT3 Tyr705 phosphorylation (Figure 54).
Furthermore, a STAT3 Y705F mutant induced Mcl1 expression and EGR1 promoter
activation to the same extent as WT STAT3. Collectively, these results suggest that the
GSK-3α/β-STAT3 signaling pathway can be triggered at EGF concentrations that do not
induce STAT3 Tyr705 phosphorylation, demonstrating that activation of STAT3dependent transcription is likely Tyr705-independent in this context.

A major implication of our results is that targeting GSK-3α/β may selectively
inhibit the actions of doubly phosphorylated STAT3. This may be desirable in
pathological conditions when GSK-3α/β-STAT3 signaling is dysregulated. We do not yet
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know the extent to which this pathway functions in vivo, but the observation that doubly
phosphorylated STAT3 is significantly elevated in clear cell renal cell carcinoma
suggests that GSK-3α/β-STAT3 signaling may be aberrantly activated in the
microenvironment of renal tumors. This is particularly important because previous
studies have shown that both GSK-3α/β and STAT3 positively regulate ccRCC
progression (208, 209, 270–272). The GSK-3α/β-STAT3 pathway that we have
described is unique in the sense that its actions generate a specific STAT3 phosphoform
that appears to be distinct from canonical pathways. We therefore speculate that the
levels of doubly phosphorylated STAT3 could be used to infer the relative activity of this
GSK-3α/β-STAT3 signaling pathway in solid tumors. Future work in our laboratory will
therefore aim to characterize the role of endothelial STAT3 in animal models of vascular
diseases and cancer. This work will serve as the basis for evaluating the roles of doubly
phosphorylated STAT3 in human physiology and disease.

Higher order information processing mechanisms like “coincidence detection” are
critical processes that allow cells to regulate discrete biological responses under a wide
range of environmental conditions (300). Our results show that the temporal spacing of
EGFR and PAR-1 activation has profound effects on endothelial cell phenotypes up to 16
hours after stimulus exposure. Remarkably, the information of simultaneous receptor
activation is processed rapidly, integrated via opposed actions of EGFR and PAR-1 on
the PI3K-AKT signaling axis, and ultimately encoded in a distinct STAT3 phosphoform
that increases the expression of STAT3 target genes in endothelial cells.
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